

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/050453 A1

(43) International Publication Date

11 April 2013 (11.04.2013)

(51) International Patent Classification:

G01N 33/68 (2006.01)

(21) International Application Number:

PCT/EP2012/069598

(22) International Filing Date:

4 October 2012 (04.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/545,042	7 October 2011 (07.10.2011)	US
61/624,943	16 April 2012 (16.04.2012)	US
61/668,841	6 July 2012 (06.07.2012)	US

(71) Applicants: **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauer Strasse 130, CH-8152 Glattpark (Opfikon) (CH). **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL, 60015 (US).

(72) Inventors: **THIELE, Michael**; Linke Bahngasse 9/24, A-1030 Wien (AT). **KERSCHBAUMER, Randolph, J**; Hoehenstrasse 19/1, A-3400 Klosterneuburg (AT). **VOELKEL, Dirk**; Stadlbreitener Anger 17, A-1220 Wien (AT). **DOUILLARD, Patrice**; Stuwerstrasse 9/9, A-1020 Wien (AT). **SCHEIFLINGER, Friedrich**; Michelbeuerngasse 4/17, A-1090 Wien (AT).

(74) Agents: **HOFFMANN · EITLE et al.**; Arabellastrasse 4, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2013/050453 A1

(54) Title: OXMIF AS A DIAGNOSTIC MARKER

(57) Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.

oxMIF AS A DIAGNOSTIC MARKER

The present invention pertains to the recognition that a specific MIF form is useful as a diagnostic marker in MIF-related diseases, in particular for example for monitoring of disease progression, as a (secondary) marker of a (MIF related) disease condition, or as a tool assisting in treatment decisions, in particular in body fluids or on cells or cell surfaces. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay.

BACKGROUND

Macrophage migration inhibitory factor (MIF) is a cytokine initially isolated based upon its ability to inhibit the *in vitro* random migration of peritoneal exudate cells from tuberculin hypersensitive guinea pigs (containing macrophages) (Bloom et al. Science 1966, 153, 80-2; David et al. PNAS 1966, 56, 72-7). Today, MIF is known as a critical upstream regulator of the innate and acquired immune response that exerts a pleiotropic spectrum of activities.

The human MIF cDNA was cloned in 1989 (Weiser et al., PNAS 1989, 86, 7522-6), and its genomic localization was mapped to chromosome 22. The product of the human MIF gene is a protein with 114 amino acids (after cleavage of the N-terminal methionine) and an apparent molecular mass of about 12.5 kDa. MIF has no significant sequence homology to any other protein. The protein crystallizes as a trimer of identical subunits. Each monomer contains two antiparallel alpha-helices that pack against a four-stranded beta-sheet. The monomer has additional two beta-strands that interact with the beta-sheets of adjacent subunits to form the interface

between monomers. The three subunits are arranged to form a barrel containing a solvent-accessible channel that runs through the center of the protein along a molecular three-fold axis (Sun et al. PNAS 1996, 93, 5191-5196).

It was reported that MIF secretion from macrophages was induced at very low concentrations of glucocorticoids (Calandra et al. Nature 1995, 377, 68-71). However, MIF also counter-regulates the effects of glucocorticoids and stimulates the secretion of other cytokines such as tumor necrosis factor TNF- α and interleukin IL-1 β (Baugh et al., Crit Care Med 2002, 30, S27-35). MIF was also shown e.g. to exhibit pro-angiogenic, pro-proliferative and anti-apoptotic properties, thereby promoting tumor cell growth (Mitchell, R.A., Cellular Signalling, 2004. 16(1): p. 13-19; Lue, H. et al., Oncogene 2007. 26(35): p. 5046-59). It is also e.g. directly associated with the growth of lymphoma, melanoma, and colon cancer (Nishihira et al. J Interferon Cytokine Res. 2000, 20:751-62).

MIF is a mediator of many pathologic conditions and thus associated with a variety of diseases including *inter alia* inflammatory bowel disease (IBD), rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), asthma, glomerulonephritis, IgA nephropathy, myocardial infarction (MI), sepsis and cancer, though not limited thereto.

Polyclonal and monoclonal anti-MIF antibodies have been developed against recombinant human MIF (Shimizu et al., FEBS Lett. 1996; 381, 199-202; Kawaguchi et al, Leukoc. Biol. 1986, 39, 223-232, and Weiser et al., Cell. Immunol. 1985, 90, 16778).

Anti-MIF antibodies have been suggested for therapeutic use. Calandra et al., (J. Inflamm. (1995); 47, 39-51) reportedly used anti-MIF antibodies to protect animals from

experimentally induced gram-negative and gram-positive septic shock. Anti-MIF antibodies were suggested as a means of therapy to modulate cytokine production in septic shock and other inflammatory disease states.

US 6,645,493 discloses monoclonal anti-MIF antibodies derived from hybridoma cells, which neutralize the biological activity of MIF. It could be shown in an animal model that these mouse-derived anti-MIF antibodies had a beneficial effect in the treatment of endotoxin induced shock.

US 200310235584 discloses methods of preparing high affinity antibodies to MIF in animals in which the MIF gene has been homozygously knocked-out.

Glycosylation-inhibiting factor (GIF) is a protein described by Galat et al. (Eur. J. Biochem, 1994, 224, 417-21). MIF and GIF are now recognized to be identical. Watarai et al. (PNAS 2000, 97, 13251-6) described polyclonal antibodies binding to different GIF epitopes to identify the biochemical nature of the posttranslational modification of GIF in Ts cells.

Watarai et al, *supra*, reported that GIF occurs in different conformational isoforms *in vitro*. One type of isomer occurs by chemical modification of a single cysteine residue. The chemical modification leads to conformational changes within the GIF protein.

As has been shown over the past decades that MIF is a molecule which is involved in a multitude of different interactions, it might therefore be a suitable marker for disease states in MIF-related diseases. Although diagnostic markers and methods for several of those diseases which are MIF-related exist, it is usually advantageous to have more than one method or marker for the diagnosis of a given disease, and - even more importantly - to have a marker which is correlated with an actual disease state. MIF is a

ubiquitous protein detectable in high amounts in the human body and therefore no clear connection between appearance of MIF and (MIF-related) diseases could be made in general. Therefore, there exists a need in the art for a suitable diagnostic marker to detect the onset and/or existence of (MIF-related) diseases in a subject; in particular, there is a need for a reliable marker which would allow monitoring of disease progression, determining a disease state and monitoring efficacy of a treatment in (MIF-related) diseases, in particular by using body fluids as samples or by using cells as samples.

DESCRIPTION OF THE INVENTION

The above objects have been solved by the present invention. In particular, the present inventors could show that oxMIF (i.e. oxidized MIF) can be detected after onset of (MIF-related) diseases, e.g. in body fluid samples, or on cells or cell surfaces and that oxMIF is correlated with a disease state and/or the disease progression. Based on the presently provided knowledge/techniques, oxMIF is not present in body fluid samples, like e.g. blood, serum and urine, from healthy donors or in cellular samples from healthy donors. OxMIF is increased under disease conditions. This increase is more pronounced (more specific) than for total MIF (see also the examples).

"is not present" in this context shall mean that oxMIF is not present in body fluids in amounts which are detectable with the ELISA-techniques as shown in Example 3.4 under the heading "Material and Methods", if carried out with the antibody RAB0, described below.

"Is not present" in the context of cellular samples, e.g. blood cells, means that in cellular samples application of the antibody RAB9 or RAB0 or RAB4 on the cells does not give

a higher signal when compared to the staining with the control antibody "Control 1" in a flow cytometry experiment as described in example 3.9.

Therefore, oxMIF is suitable as a marker for these diseases, whereby the terminology "marker in the diagnosis of a (MIF related) disease" in the context of the present invention shall mean in particular the possibility for an evaluation whether or not MIF is a factor involved in this (MIF related) disease. In that regard oxMIF as marker supplies information about the disease state, its progression and serves as a marker to determine effectiveness of a given treatment; in addition, oxMIF detection in a sample, e.g. a body fluid sample or a cell sample, can serve as an indicator for a preferred anti-MIF therapy. The detection of oxMIF thus serves to improve known diagnostic techniques in a given disease or disorder. It assists the practitioner in his or her decision how to treat a given disease or disorder and helps to improve specificity of the diagnosis. oxMIF is thus a specific and suitable secondary marker. Its detection can thus serve as an adjunctive test in the management of patients afflicted with MIF related diseases. The disease in question is in a preferred embodiment a disease which is known or suspected to be MIF related (see the diseases mentioned in detail below) but can also be a disease which had so far not been suspected to be MIF related.

In a preferred embodiment, the detection of oxMIF presence in a sample would indicate to the practitioner that the subject, from whom (or which) the sample has been taken, might benefit from a therapy directed against MIF. Such a therapy could be selected from anti-MIF molecules, e.g. anti-(ox)MIF antibodies or small molecules which are directed against (ox)MIF.

Elevated MIF levels, i.e. levels of MIF in general are detected after the onset of various diseases, *inter alia* after the onset of cancer. However, MIF circulates also in healthy subjects, which makes a clear differentiation difficult. oxMIF, on the contrary, is not present in healthy subjects and therefore is a much stronger diagnostic marker for MIF-related diseases. As shown in the examples, oxMIF is increased in disease states and detectable in samples of patients, like e.g. blood, serum and urine.

The invention presented here is based - *inter alia* - on the finding that the Baxter antibodies RAB9, RAB4 and RAB0 specifically bind to oxMIF (and are incapable of binding to redMIF).

In earlier experiments carried out by the inventors, it could be shown that oxidative procedures like cystine-mediated oxidation, GSSG (ox. Glutathione)-mediated oxidation or incubation of MIF with Proclin300 or protein crosslinkers (e.g. BMOE) causes binding to the above mentioned antibodies.

The surprising conclusions reached by the present inventors are:

- Redox modulation (Cys/Glu-mediated mild oxidation) of recombinant MIF (human, murine, rat, CHO, monkey)) or treatment of recombinant MIF with Proclin300 or protein crosslinkers leads to the binding of Baxter's anti-MIF antibodies RAB9, RAB4 and RAB0
- Reduction of oxMIF leads to the loss of Ab binding
- Specificity for oxMIF-isoforms correlates with biological Ab efficacy (*in vitro/in vivo*).
- oxMIF levels can be correlated with a disease state.

Thus, the present invention is preferably defined as follows:

1. Use of oxMIF as a marker in the *in vitro* diagnosis of (MIF-related) diseases, wherein oxMIF is MIF which is differentially binding to antibody RAB9, RAB0 and/or RAB4.
2. The use of item 1 wherein said diagnosis of (MIF-related diseases) further involves the use of compounds differentially binding to the diagnostic marker, which is oxMIF, as defined in item 1.
3. The use according to item 2 wherein the compounds are antibodies, differentially binding to oxMIF.
4. The use according to item 3 wherein the antibodies bind to oxMIF, but do not bind to red MIF.
5. The use according to item 4 wherein the differential binding is a binding to oxMIF which occurs with a K_D value of less than 100 nM, preferably less than 50 nM, even more preferred less than 10nM and a non-binding to redMIF which is characterized by a K_D of more than 400 nM.
6. The use according to any one or more of items 1 to 5, wherein the MIF-related diseases are selected from the group comprising: inflammatory diseases and neoplastic diseases (benign, pre-malignant and/or malignant).
7. The use according to item 6 wherein the MIF-related diseases are selected from the group, consisting of colon cancer, prostate cancer, bladder cancer, pancreas cancer, ovarian cancer, melanoma, lymphoma, hepatocellular carcinoma, asthma, ARDS, rheumatoid arthritis, sepsis, IgA nephropathy, glomerulonephritis, Lupus Nephritis (LN), hepatitis, pancreatitis (+/- acute lung injury), Crohn's disease, ulcerative colitis,

gastric ulcer, Alzheimer's disease, multiple sclerosis, Guillain-Barre syndrome, cardiac dysfunction, angioplasty, atherosclerosis, myocarditis, type 1 diabetes, diabetic retinopathy, age-related macula degeneration (AMD), atopic dermatitis, psoriasis, endometriosis, neuropathic pain and/or uveitis.

8. The use according to any one or more of items 2 to 7 wherein the antibodies are selected from the group consisting of oxMIF binders (like e.g. antibodies RAB9, RAB4 and/or RAB0)).
9. The use according to any one of items 1 to 8, wherein the diagnosis is the diagnosis of the existence of a (MIF-related disease), the diagnosis of progression of a (MIF-related disease), the diagnosis of the state of a disease, and/or the monitoring of effectiveness of a treatment.
10. The use according to any one of items 1 to 9, wherein the diagnosis is carried out on a body fluid sample of a subject.
11. The use according to any one of items 1 to 9, wherein the diagnosis is carried out on a cellular sample of a subject.
12. A diagnostic assay for *in vitro* diagnosis of (MIF-related) diseases by detection of oxMIF as defined in item 1 in a body fluid or a cellular sample of a subject, comprising a step of determining binding of a compound to oxMIF in said sample *in vitro*.
13. The diagnostic assay according to item 12 wherein the compound binding to oxMIF and the (MIF-related) diseases are as defined in any one or more of items 2 to 9.

14. The diagnostic assay according to item 12 or 13, wherein the assay is repeated once or several times during progression, remission and/or treatment of a (MIF-related) disease.
15. Use of a diagnostic kit in the assay of any one or more of items 12 to 14, wherein the diagnostic kit comprises a compound binding to oxMIF.
16. The use according to item 15 wherein the kit additionally comprises buffers, controls (e.g. recombinant (ox)MIF), polyclonal MIF antibody, and/or conjugated detection antibody.
17. Anti-MIF antibody, which is selected from the following group:
 - a) a RAB4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25110 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25112,
 - b) a RAB9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25111 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25113,
 - c) a RAB0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25114 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25115,
 - d) a RAM4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25861 and a heavy chain

sequence as deposited by way of plasmid deposition with deposit number DSM 25862,

- e) a RAM9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25859 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25860, and/or
- f) a RAM0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25863 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25864.

18. Anti-MIF antibody, which is selected from the following group:

- a) a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6,
- b) a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5,
- c) a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7,
- d) a RAB2 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 4 and a heavy chain amino acid sequence of SEQ ID NO:8,
- e) a RAM4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 14 and a heavy chain amino acid sequence of SEQ ID NO:13,
- f) a RAM9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 12 and a heavy chain amino acid sequence of SEQ ID NO: 11, and/or

- g) a RAM0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 10 and a heavy chain amino acid sequence of SEQ ID NO: 9
- h) or functional equivalents thereof which are characterized by binding to the same epitope as any one of the antibodies a) to g) above.
19. Use of any one of the above antibodies, in particular as defined in items 17 or 18, in the diagnosis of a (MIF-related) disease.

All above mentioned items as well as the claims annexed hereto pertain equally to the following preferred antibodies:

RAM9

RAM4

RAM0.

These antibodies have the same specificities as the antibodies mentioned in the above list of items (see also below); similar results can be achieved with these antibodies.

In particular, with the present invention, preferred inventive antibodies, which are particularly suitable and advantageous, e.g. as diagnostic markers, are provided.

These above mentioned antibodies are characterized and supported by both their sequences as well as by deposits as plasmids in *E.coli* (strain TG1), comprising either the light or the heavy chain of each of the above mentioned antibodies RAB0, RAB4 and RAB9, respectively as well as of RAM0, RAM4 and RAM9.

The plasmids are characterized by their DSM number which is the official number as obtained upon deposit under the Budapest Treaty with the German Collection of Microorganisms and Cell Cultures (DSMZ), Mascheroder Weg 1b, Braunschweig, Germany. The plasmids were deposited in *E. coli* strains, respectively.

The plasmid with the DSM 25110 number comprises the light chain sequence of the anti-MIF antibody RAB4.

The plasmid with the DSM 25112 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB4.

The co-expression of plasmids DSM 25110 and DSM 25112 in a suitable host cell results in the production of preferred anti-MIF antibody RAB4.

The plasmid with the DSM 25111 number comprises the light chain sequence of the anti-MIF antibody RAB9.

The plasmid with the DSM 25113 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB9.

The co-expression of plasmids DSM 25111 and DSM 25113 in a suitable host cell results in the production of preferred anti-MIF antibody RAB9.

The plasmid with the DSM 25114 number comprises the light chain sequence of the anti-MIF antibody RAB0.

The plasmid with the DSM 25115 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB0.

The co-expression of plasmids DSM 25114 and DSM 25115 in a suitable host cell results in the production of preferred anti-MIF antibody RAB0.

Also deposited are antibodies RAM0, RAM9 and RAM4; all have been deposited with the DSZM, Braunschweig, Germany on April 12, 2012 according to the Budapest Treaty, with the following designations:

RAM9 - heavy chain: E.coli GA.662-01.pRAM9hc - DSM 25860.
RAM4 - light chain: E.coli GA.906-04.pRAM4lc - DSM 25861.
RAM9 - light chain: E.coli GA.661-01.pRAM9lc - DSM 25859.
RAM4 - heavy chain: E.coli GA.657-02.pRAM4hc - DSM 25862.
RAM0 - light chain: E.coli GA.906-01.pRAM0lc - DSM 25863.
RAM0 - heavy chain: E.coli GA.784-01.pRAM0hc - DSM 25864.

The invention thus also encompasses a diagnostic assay comprising an anti-oxMIF antibody or antigen-binding fragment thereof whereby these antibodies or antigen-binding fragments thereof have a differential binding, i.e. bind to oxMIF but do not bind to redMIF for use in diagnostic methods. Based on the current knowledge/techniques, oxMIF cannot be detected in samples from healthy donors. In one embodiment the above anti-oxMIF antibody or antigen-binding portion thereof can be used to detect human oxMIF in a biological sample from a human subject.

A biological sample in the context of this application is preferably a body fluid sample of the subject on which/whom the diagnosis shall be performed. A body fluid sample is any sample of a body fluid as known to a person skilled in the art. Exemplary, but not limiting, such a sample can be blood, plasma, serum, saliva, urine, nasal fluid, ascites, ocular fluid, amniotic fluid, aqueous humour, vitreous humour, tear fluid, Cowper's fluid, semen, interstitial fluid, lymph, breast milk, mucus (incl. snot and phlegm), pleural fluid, pus, menses, vaginal lubrication, sebum, cerebrospinal fluid and synovial fluid. Further biological samples in the context of this application can be lavages (washing outs) of a

(hollow) body organ (e.g. bronchoalveolar lavage, stomach lavage and bowel lavage).

A biological sample in the context of this application in an alternative embodiment, is a cell sample, most preferably a cell sample from the circulation or the diseased tissue, more preferably as a single cell suspension sample, of the subject on which the diagnosis shall be performed.

In particular, the above diagnostic assay can be used to determine whether (ox)MIF is involved in a given disease.

The present invention thus also pertains to a method for evaluating the progression of a disease; in the present context the term "state of a disease" is to be understood as synonymous with the term "severity of a disease" and refers to the seriousness, degree or state (i.e. stage) of a disease or condition. For example, a disease may be characterised as mild, moderate or severe. The determination or assessment of the degree of severity or the degree, i.e. state of the disease is well known to a person skilled in the art. The actual method which will be carried out for this assessment of course depends on the disease or condition in question. For example, the state of a disease may be determined by comparing the likelihood or length of survival of a subject having a disease with the likelihood or length of survival in other subjects having the same disease.

In other embodiments the state of the disease may be determined by comparing the symptoms of a disease in a subject having a disease with the symptoms in other subjects having the same disease. In yet another embodiment the state of the disease and its progression is reflected by the change of symptoms within one and the same patient over a period of time.

In a further preferred aspect, the present invention can also be directed to a method of selecting a subject as being eligible for a treatment with an anti-(ox)MIF compound, wherein the subject has a (MIF-related) disease, or is at risk of developing a (MIF-related) disease, comprising detecting the existence and/or level and/or change of level of oxMIF in said subject. A subject having an elevated level of oxMIF can be selected for a prophylactic or therapeutic treatment with an anti (ox)MIF compound as defined above.

The term "prophylactic" or "therapeutic" treatment is art-recognized and refers to administration of a drug to a patient. If it is administered prior to clinical manifestation of the unwanted condition (e.g. disease or other unwanted state of the host, e.g. a human or an animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects thereof).

As used herein an anti-(ox)MIF compound refers to any agent that attenuates, inhibits, opposes, counteracts, or decreases the biological activity of (ox)MIF. An anti(ox)MIF compound may be an agent that inhibits or neutralizes (ox)MIF activity, for example an antibody, particularly preferred, the antibodies as described herein, even more preferred the antibodies RAB9, RAB4 and/or RAB0.

The diagnostic assay can be used to determine an oxMIF presence or level in e.g. body fluid samples or cellular samples of patients. The presence or absence of oxMIF is suitable to distinguish, if the disease if MIF relevant or to decide of oxMIF treatment is reasonable. OxMIF levels indicate disease progression or treatment efficacy.

The invention further relates to kits comprising an anti-oxMIF antibody or an antigen-binding portion thereof according to the invention. A kit may include in addition to the antibody, further diagnostic or therapeutic agents and uses thereof. A kit also can include instructions for use in a diagnostic or therapeutic method.

DETAILED DESCRIPTION OF THE INVENTION

The invention is further described in the figures as enclosed.

Description of the figures:

Figure 1: TotalMIF and oxMIF in plasma of *E.coli* challenged mice

Plasma obtained from control mice (C) and *E.coli* challenged mice (E) were subjected to oxMIF (Figure 1A) and total MIF (Figure 1B) ELISAs.

Figure 2: oxMIF detection on the surface of granulocytes and monocytes from *E.coli* challenged mice

Blood samples obtained at different time points from control (F) or *E.coli* challenged mice (E) were stained with specific cell markers to discriminate the leukocyte populations, and human anti-MIF monoclonal antibody RAB9 or human control IgG1 detected by an RPE (R-phycoerythrin, a chromogenic marker)-labeled polyclonal anti-human IgG.

Histograms are showing overlays of the control antibody (thick black line) with the RAB9 specific staining (grey profile) in the granulocyte population (GR1) or the monocyte population (CD14).

Figure 3: Total MIF and oxMIF detection in plasma of bacteriemic patients

Total MIF and oxMIF levels in plasma from bacteriemic patients (1 to 6, black columns), one healthy control (7, grey column) and a pool of plasma from healthy donors (8, grey column) were assessed by ELISA.

Figure 4: Detection of oxMIF in serum samples of psoriasis patients.

Decrease of oxMIF levels in the circulation of the patients show correlation with the improvement of disease severity.

Figure 5: Level of oxMIF in urine from rats with glomerulonephritis.

(A) Levels of oxMIF increase with disease progression from day 0 (before disease induction) to day 8 after disease induction. Treatment with anti-MIF antibody RAB9 reduces urinary levels of oxMIF on day 8. (B) Macrophage infiltration determined in the same experiment after sacrificing the animals on day 8. Reduced macrophage infiltration in the RAB9 treated group correlates with reduced oxMIF levels.

Figure 6: Level of oxMIF in urine from patients with Lupus Nephritis.

(A) OxMIF levels in urine correlates with disease severity. Mean values measured for each patient group are shown. (B) Time course of oxMIF levels measured in one patient newly diagnosed with Lupus Nephritis. The patient was treated with unspecific immunosuppressive drugs and reduction of urinary oxMIF levels correlates with improved clinical situation. (C) OxMIF levels in the plasma

correlates with disease severity. Mean values measured for each patient group are shown.

Figure 7: Total MIF and oxMIF in the aqueous humor from patients with diabetic retinopathy
Total MIF and oxMIF levels in aqueous humor obtained from patients with cataract (CAT, n=5) or diabetic retinopathy (DR, n=5) were assessed by ELISA

Figure 8: Xenograft mouse model for prostate cancer
After termination of the animal model plasma samples from the mice have been taken to measure total MIF levels (A) as well as oxMIF levels (B). Tumors have been excised and weighed (C). The figures show the mean of the values obtained for each group. Plasma samples from non-xenografted mice were also analyzed for total MIF and oxMIF (= negative control).

Figure 9: oxMIF on the surface of the PC-3 prostate cancer cell line
PC-3 cells were first labelled with a control human IgG1 monoclonal antibody (grey tinted graph) and with RAB9 (black line). Detection of cell surface bound antibodies was done with an RPE-labelled rabbit anti-human IgG.

Figure 10: Absence of oxMIF on the surface of leukocytes from healthy donors
Human blood cells from healthy donors were incubated with a control IgG1 human monoclonal antibody (grey tinted graph), with RAB9 (black line) or with RAB0 (black dotted line). Detection of cell surface bound antibodies was done with an RPE-labelled rabbit anti-human IgG. Electronic

gating enabled us to distinguish between the granulocytes, monocytes, lymphocyte B cells (CD19⁺ cells) and lymphocyte T cells + Natural Killer cells (CD19^{neg} cells).

Figure 11: oxMIF on the surface of the BxPC3 pancreatic cancer cell line

BxPC3 cells were first labelled with a control human IgG1 monoclonal antibody (grey tinted graph) or with RAB0 (black line). Detection of cell surface bound antibodies was done with an RPE-labelled rabbit anti-human IgG.

Figure 12: oxMIF on the surface of the A2780 ovarian cancer cell line

A2780 cells were first labelled with a control human IgG1 monoclonal antibody (grey tinted graph), with RAB9 (black line). Detection of cell surface bound antibodies was done with an RPE-labelled rabbit anti-human IgG.

Figure 13: oxMIF on the surface of human lymphoma cell line

Human lymphoma cell lines were first labelled with a control human IgG1 monoclonal antibody (grey tinted graph), with RAB9 (black line in A, B and D), or with RAB0 (black line in C). Detection of cell surface bound antibodies was done with an RPE-labelled rabbit anti-human IgG. A) CA46 Burkitt's lymphoma; B) MC-CAR B lymphocyte myeloma; C) Raji Burkitt's lymphoma; D) U937 histiocytic lymphoma.

Figure 14: Levels of total MIF and oxMIF in plasma from prostate cancer patients

(A) Total MIF levels were measured in plasma from different prostate cancer patients (n=14) and from healthy volunteers (n=49). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0166, *t* test unpaired one tail

(B) oxMIF levels were measured in plasma from different prostate cancer patients (n=14) and from healthy volunteers (n=49). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0016, *t test* unpaired one tail

Figure 15: Levels of total MIF and oxMIF in plasma from breast cancer patients

(A) Total MIF levels were measured in plasma from different breast cancer patients (n=15) and from healthy volunteers (n=49). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0078, *t test* unpaired one tail

(B) oxMIF levels were measured in plasma from different breast cancer patients (n=15) and from healthy volunteers (n=49). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0451, *t test* unpaired one tail

Figure 16: Levels of total MIF and oxMIF in cerebrospinal fluid from patients with multiple sclerosis

(A) Total MIF levels were measured in cerebrospinal fluids from patients diagnosed with different forms of multiple sclerosis (n=49) and from healthy volunteers (n=30). Box and whiskers (5-95% percentile) are shown with medians (bold line). Statistics: p<0.0001, *t test* unpaired one tail

(B) oxMIF levels were measured in cerebrospinal fluids from patients diagnosed with different forms of multiple sclerosis (n=49) and from healthy volunteers (n=30). Box and whiskers (5-95% percentile) are shown with medians (bold line). Statistics: p<0.0001, *t test* unpaired one tail

Figure 17: Levels of total MIF and oxMIF in plasma from ovarian cancer patients

(A) Total MIF levels were measured in plasma from different ovarian cancer patients (n=42) and from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0434, *t test* unpaired one tail

(B) oxMIF levels were measured in plasma from different ovarian cancer patients (n=42) and from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold. Statistics: p=0.0663, t test unpaired one tail

(C) Total MIF levels were measured in plasma from different kind of ovarian cancer patients (clear cell adenocarcinoma n=7, papillary serous cystadenocarcinoma n=14, and serous cystadenocarcinoma n=21) and from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold. Statistical significance was assessed using the t test (unpaired one tail) for each group against the control group:

- a. Controls (n=19) vs Clear Cell Adenocarcinoma (n=7): p=0.3696
- b. Controls (n=19) vs Papillary Serous Cystadenocarcinoma (n=14): p=0.0721
- c. Controls (n=19) vs Serous Cystadenocarcinoma (n=21): p=0.0046**

(D) oxMIF levels were measured in plasma from different kind of ovarian cancer patients (clear cell adenocarcinoma n=7, papillary serous cystadenocarcinoma n=14, and serous cystadenocarcinoma n=21) and from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold. Statistical significance was assessed using the t test (unpaired one tail) for each group against the control group:

- a. Controls (n=19) vs Clear Cell Adenocarcinoma (n=7): p=0.4518
- b. Controls (n=19) vs Papillary Serous Cystadenocarcinoma (n=14): p=0.0438*
- c. Controls (n=19) vs Serous Cystadenocarcinoma (n=21): p=0.0357*

Figure 17A: Levels of total MIF in plasma from ovarian cancer patients

Figure 17B: Levels of oxMIF in plasma from ovarian cancer patients

Figure 17C: Levels of total MIF in plasma from patients with different forms of ovarian cancer

Figure 17D: Levels of oxMIF in plasma from patients with different forms of ovarian cancer

Figure 18: Levels of total MIF and oxMIF in plasma from UC and CD patients

- (A) Total MIF levels were measured in plasma from different UC (n=15) and CD patients (n=21), as well as from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold.
- a. Controls vs UC: p=0.1240, *t test* unpaired one tail
 - b. Controls vs CD: p=0.0207*, *t test* unpaired one tail
- (B) oxMIF levels were measured in plasma from different UC (n=15) and CD patients (n=21), as well as from healthy volunteers (n=19). Box and whiskers (5-95% percentile) are shown with median in bold.
- a. Controls vs UC: p=0.0417*, *t test* unpaired one tail
 - b. Controls vs CD: p=0.0114*, *t test* unpaired one tail

Figure 18A: Levels of total MIF in plasma from patients with UC and CD

Figure 18B: Levels of oxMIF in plasma from patients with UC and CD

Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present

specification unless otherwise indicated. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), which are incorporated herein by reference.

"MIF" or "macrophage migration inhibitory factor" refers to the protein, which is known as a critical mediator in the immune and inflammatory response, and as a counterregulator of glucocorticoids. MIF includes mammalian MIF, specifically human MIF (Swiss-Prot primary accession number: P14174), wherein the monomeric form is encoded as a 115 amino acid protein but is produced as a 114 amino acid protein due to cleavage of the initial methionine. "MIF" also includes "GIF" (glycosylation-inhibiting factor) and other forms of MIF such as fusion proteins of MIF. The numbering of the amino acids of MIF starts with the N-terminal methionine (amino acid 1) and ends with the C-terminal alanine (amino acid 115).

"oxidized MIF" or oxMIF is defined for the purposes of the invention as an isoform of MIF that occurs by treatment of MIF with mild oxidizing reagents, such as Cystine. As has been shown by the present invention, recombinant oxMIF that has been treated this way comprises isoform(s) of MIF that share structural rearrangements with oxMIF that (e.g.) occurs *in vivo* after challenge of animals with bacteria.

redMIF is defined for the purposes of this invention as reduced MIF and is MIF which does not bind to RAB0, RAB9 and/or RAB4.

The anti-oxMIF antibodies described in this invention are able to discriminate between ox and red MIF, which are

generated by mild oxidation or reduction, respectively, and are useful to specifically detect oxMIF. Discrimination between these conformers is assessed by ELISA (e.g. as described in example 3.4) or surface plasmon resonance.

Assessing differential binding of the antibodies by Biacore.

Binding kinetics of oxMIF and redMIF to antibody RAB9 and RAB0 are examined by surface plasmon resonance analysis using a Biacore 3000 System. The antibodies were coated on a CM5 (= carboxymethylated dextran) chip and recombinant MIF protein, pre-incubated with 0.2% Proclin300, were injected.

(Proclin300 consists of oxidative isothiazolones that stabilize the oxMIF structure by avoiding a conversion of oxMIF to redMIF). In native HBS-EP buffer (= Biacore running buffer) without addition of ProClin300, none of the recombinant MIF proteins bound to RAB9, RAB0 or to the reference antibody (irrelevant isotype control antibody) used as negative (background) binding control.

In a preferred embodiment, oxMIF is MIF which is differentially bound by antibody RAB9, RAB4 and/or RAB0 or an antigen-binding fragment thereof, meaning that these antibodies do bind to oxMIF while redMIF is not bound by either one of these antibodies.

In other embodiments, the anti-oxMIF antibodies, e.g. the antibodies mentioned above or an antigen-binding portion thereof bind oxMIF with a K_D of less than 100 nM, preferably a K_D of less than 50 nM, even more preferred with a K_D of less than 10 nM. Particularly preferred, the antibodies of this invention bind to oxMIF with a K_D of less than 5 nM.

(Non-)binding of an antibody, e.g. RAB9, RAB4 or RAB0 (to oxMIF or redMIF) can be determined as generally known to a person skilled in the art, examples being any one of the

following methods: Differential Binding ELISA with recombinant MIF, or surface plasmon resonance using recombinant MIF in its reduced or oxidized state, like the well known Biacore assay, described above.

A preferred method for the determination of binding is surface plasmon resonance of an antibody to e.g. rec. (ox)MIF whereupon "binding" is meant to be represented by a K_D of less than 100 nM preferably less than 50 nM, even more preferred less than 10 nM whereas the non-binding to redMIF is characterized by a K_D of more than 400 nM. "Binding" and "specific binding" is used interchangeably here to denote the above. "Differential binding" in the context of this application means that a compound, in particular the antibodies as described herein, bind to oxMIF (e.g. with the K_D values mentioned above) while they do not bind to redMIF (with non-binding again being defined as above).

An "antibody" refers to an intact antibody or an antigen-binding portion that competes with the intact antibody for (specific) binding. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference). The term antibody includes human antibodies, mammalian antibodies, isolated antibodies and genetically engineered forms such as chimeric, camelized or humanized antibodies, though not being limited thereto.

The term "antigen-binding portion" of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g. (ox)MIF). Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include e.g. - though not limited thereto - the following: Fab, Fab', F(ab')₂, Fv, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies,

antibodies and polypeptides that contain at least a portion of an antibody that is sufficient to confer specific antigen binding to the polypeptide, i.e. ox or redMIF. From N-terminus to C-terminus, both the mature light and heavy chain variable domains comprise the regions FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia et al. J. Mol. Biol. 196:901-917 (1987), or Chothia et al., Nature 342:878-883 (1989). An antibody or antigen-binding portion thereof can be derivatized or linked to another functional molecule (e.g., another peptide or protein). For example, an antibody or antigen- binding portion thereof can be functionally linked to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a linking molecule.

The term "KD" refers here, in accordance with the general knowledge of a person skilled in the art to the equilibrium dissociation constant of a particular antibody with the respective antigen. This equilibrium dissociation constant measures the propensity of a larger object (here: complex ox or red MIF/antibody) to separate, i.e. dissociate into smaller components (here: ox or redMIF and antibody).

The term "human antibody" refers to any antibody in which the variable and constant domains are human sequences. The term encompasses antibodies with sequences derived from human genes, but which have been changed, e.g. to decrease possible immunogenicity, increase affinity, eliminate cysteines that might cause undesirable folding, etc. The term encompasses such antibodies produced recombinantly in non-human cells, which might e.g. impart glycosylation not typical of human cells.

The term "humanized antibody" refers to antibodies comprising human sequences and containing also non-human sequences.

The term "camelized antibody" refers to antibodies wherein the antibody structure or sequences has been changed to more closely resemble antibodies from camels, also designated camelid antibodies. Methods for the design and production of camelized antibodies are part of the general knowledge of a person skilled in the art.

The term "chimeric antibody" refers to an antibody that comprises regions from two or more different species.

The term "isolated antibody" or "isolated antigen-binding portion thereof" refers to an antibody or an antigen-binding portion thereof that has been identified and selected from an antibody source such as a phage display library or a B-cell repertoire.

The production of the anti-(ox)MIF antibodies according to the present invention includes any method for the generation of recombinant DNA by genetic engineering, e.g. via reverse transcription of RNA and/or amplification of DNA and cloning into expression vectors. In some embodiments, the vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. In some embodiments, the vector is capable of autonomous replication in a host cell into which it is introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). In other embodiments, the vector (e.g. non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein

as "recombinant expression vectors" (or simply, "expression vectors").

Anti-(ox)MIF antibodies can be produced *inter alia* by means of conventional expression vectors, such as bacterial vectors (e.g., pBR322 and its derivatives), or eukaryotic vectors. Those sequences that encode the antibody can be provided with regulatory sequences that regulate the replication, expression and/or secretion from the host cell. These regulatory sequences comprise, for instance, promoters (e.g., CMV or SV40) and signal sequences. The expression vectors can also comprise selection and amplification markers, such as the dihydrofolate reductase gene (DHFR), hygromycin-B-phosphotransferase, and thymidine-kinase. The components of the vectors used, such as selection markers, replicons, enhancers, can either be commercially obtained or prepared by means of conventional methods. The vectors can be constructed for the expression in various cell cultures, e.g., in mammalian cells such as CHO, COS, HEK293, NSO, fibroblasts, insect cells, yeast or bacteria such as *E.coli*. In some instances, cells are used that allow for optimal glycosylation of the expressed protein.

The anti-(ox)MIF antibody light chain gene(s) and the anti-(ox)MIF antibody heavy chain gene(s) can be inserted into separate vectors or the genes are inserted into the same expression vector. The antibody genes are inserted into the expression vector by standard methods, e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present.

The production of anti-(ox)MIF antibodies or antigen-binding fragments thereof may include any method known in the art for the introduction of recombinant DNA into eukaryotic cells by transfection, e.g. via electroporation or microinjection. For

example, the recombinant expression of anti-(ox)MIF antibody can be achieved by introducing an expression plasmid containing the anti-(ox)MIF antibody encoding DNA sequence under the control of one or more regulating sequences such as a strong promoter, into a suitable host cell line, by an appropriate transfection method resulting in cells having the introduced sequences stably integrated into the genome. The lipofection method is an example of a transfection method which may be used according to the present invention.

The production of anti-(ox)MIF antibodies may also include any method known in the art for the cultivation of said transformed cells, e.g. in a continuous or batchwise manner, and the expression of the anti-(ox)MIF antibody, e.g. constitutive or upon induction. It is referred in particular to WO 2009/086920 for further reference for the production of anti-(ox)MIF antibodies. In a preferred embodiment, the anti-(ox)MIF antibodies as produced according to the present invention bind to oxMIF or an epitope thereof. Particularly preferred antibodies in accordance with the present invention are antibodies RAB9, RAB4 and/or RAB0 as well as RAM9, RAM4 and/or RAM0.

The sequences of these antibodies are partly also disclosed in WO 2009/086920; see in addition the sequence list of the present application and the following:

SEQ ID NO: 1 for the amino acid sequence of the light chain of RAB9:

DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV
ASHSQSGVPS RFRGSGSETD FTLTISGLQP EDSATYYCQQ SFWTPLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEC,

SEQ ID NO: 2 for the amino acid sequence of the light chain of RAB4:

DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY
GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc,

SEQ ID NO: 3 for the amino acid sequence of the light chain of RAB0:

DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY
GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc,

SEQ ID NO: 4 for the amino acid sequence of the light chain of RAB2:

DIQMTQSPVT LSLSPGERAT LSCRASQSVR SSYLAWSQQK PGQTPLLLIY
GASN RATGIP DRFSGSGSGT DFTLTISRL E PEDFAVYYCQ QYGN SLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc,

SEQ ID NO: 5 for the amino acid sequence of the heavy chain of RAB9:

EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS
IGSSGGTTYY ADSVKGRFTI SRDNSKNLTY LQMNSLRAED TAVYYCAGSQ
WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PCRSRSTSEST AALGCLVKDY
FPEPVTWSN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGKTYT
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPPKDTL
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTL
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TPPVLDSDG
SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK,

SEQ ID NO: 6 for the amino acid sequence of the heavy chain of RAB4:

EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG
IVPSGGFTKY ADSVKGRFTI SRDNSKNLTY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVWGQG TT TVTVSSAST KGPSVFPLA CSRSTSESTA
ALGCLVKDYF PEPVTWSN GALTSGVHTF PAVLQSSGLY SLSSVVTVPs

SSLGTTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPPKPDTLMI SRTPEVTCVV DVDSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK,

SEQ ID NO: 7 for the amino acid sequence of the heavy chain of RAB0:

EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG
IYPSGGRTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVGQG TTGTVSSAST KGPSVFPLAP CSRSTSESTA
ALGCLVKDYF PEPVTWSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPPKPDTLMI SRTPEVTCVV DVDSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK,

SEQ ID NO: 8 for the amino acid sequence of the heavy chain of RAB2:

EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG
IYPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVGQG TTGTVSSAST KGPSVFPLAP CSRSTSESTA
ALGCLVKDYF PEPVTWSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS
SSLGTTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF
PPPKPDTLMI SRTPEVTCVV DVDSQEDPEV QFNWYVDGVE VHNAKTKPRE
EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP
REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL
SLGK.

SEQ ID NO: 9 for the amino acid sequence of RAM0hc:

EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG
IYPSGGRTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN

VIAVAGTGYY YYGMDVWGQG TTGTVSSAST KGPSVFPLAP SSKSTSGGTA
ALGCLVKDYF PEPVTWSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVP
SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
YKTTPPVLDs DGSFFLYSKL TVDKSRWQOG NVFSCSVMHE ALHNHYTQKS
LSLSPGK.

SEQ ID NO: 10 for the amino acid sequence of RAM01c:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY
GTSSRATGIP DRFGSGASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc.

SEQ ID NO: 11 for the amino acid sequence of RAM9hc:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS
IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ
WLYGMDVWGQ GTTGTTSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY
FPEPVTWSWNS SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD
SDGSFFLYSK LTVDKSRWQO GNVFSCSVMH EALHNHYTQK SLSLSPGK.

SEQ ID NO: 12 for the amino acid sequence of RAM9lc:
DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV
ASHSQSGVPS RFRGSGSETD FTTLTISGLQP EDSATYYCQQ SFWTPLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc.

SEQ ID NO: 13 for the amino acid sequence of RAM4hc:
EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG
IVPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN
VIAVAGTGYY YYGMDVWGQG TTGTVSSAST KGPSVFPLAP SSKSTSGGTA
ALGCLVKDYF PEPVTWSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPs

SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNNAKTK
PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
YKTTPPVLDs DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS
LSLSPGK.

SEQ ID NO: 14 for the amino acid sequence of RAM4lc:
DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWSQQK PGQAPRLLIY
GTSSRATGIP DRFSGSASGT DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG
LSSPVTKSFN RGEc.

The anti-MIF antibody of the invention is preferably an isolated monoclonal antibody. The anti-MIF antibody can be an IgG, an IgM, an IgE, an IgA, or an IgD molecule. In other embodiments, the anti-MIF antibody is an IgG1, IgG2, IgG3 or IgG4 subclass. In other embodiments, the antibody is either subclass IgG1 or IgG4. In other embodiments, the antibody is subclass IgG4. In some embodiments, the IgG4 antibody has a single mutation changing the serine (serine228, according to the Kabat numbering scheme) to proline. Accordingly, the CPSC sub-sequence in the Fc region of IgG4 becomes CPPC, which is a sub-sequence in IgG1 (Angal et al. Mol Immunol. 1993, 30, 105-108).

Additionally, the production of anti-(ox)MIF antibodies may include any method known in the art for the purification of an antibody, e.g. via anion exchange chromatography or affinity chromatography. In one embodiment the anti-(ox)MIF antibody can be purified from cell culture supernatants by size exclusion chromatography.

The terms "center region" and "C-terminal region" of MIF refer to the region of human MIF comprising amino acids 35-68

and aa 86-115, respectively, preferably aa 50-68 and aa 86 to 102 of human MIF, respectively.

Particularly preferred antibodies of the present invention bind to either region aa 50-68 or region aa 86-102 of human MIF. This is also reflected by the binding of the preferred antibodies RAB0, RAB4 RAB2 and RAB9 as well as RAM4, RAM9 and RAM0 which bind as follows:

RAB4 and RAM4: aa 86-102

RAB9 and RAM9: aa 50-68

RAB0 and RAM0: aa 86-102

RAB2: aa 86 - 102

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or an antibody fragment. Epitopic determinants usually consist of chemically active surface groupings of molecules such as exposed amino acids, amino sugars, or other carbohydrate side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.

The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In some embodiments, the vector is a plasmid, i.e., a circular double stranded DNA loop into which additional DNA segments may be ligated.

The term "host cell" refers to a cell line, which is capable to produce a recombinant protein after introducing an expression vector. The term "recombinant cell line", refers to a cell line into which a recombinant expression vector has been introduced. It should be understood that "recombinant cell line" means not only the particular subject cell line but also the progeny of such a cell line. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may

not, in fact, be identical to the parent cell, but are still included within the scope of the term "recombinant cell line" as used herein.

The host cell type according to the present invention is e.g. a COS cell, a CHO cell or e.g. an HEK293 cell, or any other host cell known to a person skilled in the art, thus also for example including bacterial cells, like e.g. *E.coli* cells.

In one embodiment, the anti-MIF antibody is expressed in a DHFR-deficient CHO cell line, e.g., DXB11, and with the addition of G418 as a selection marker. When recombinant expression vectors encoding antibody genes are introduced into CHO host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or secretion of the antibody into the culture medium in which the host cells are grown.

Anti-(ox)MIF antibodies can be recovered from the culture medium using standard protein purification methods.

A "MIF-related disease" in the present context refers generally to infectious diseases, inflammation, autoimmunity, cancer, cell differentiation and atherogenesis. MIF-related diseases are e.g., type I and II-diabetes, acute lung injury, asthma, allograft-rejection, graft-versus-host-disease, wound healing disturbances and inflammatory bowel disease.

Further, cancer is a MIF-related disease. In particular, MIF-related cancers are lymphoma, sarcoma, prostatic cancer and colon cancer, bladder cancer, pancreas cancer, ovarian cancer, melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer and pancreatic cancer.

Further, atherosclerosis is a MIF-related disease.

Further MIF-related diseases are sarcoidosis, scleroderma, psoriasis, (ulcerative) colitis, as well atopic dermatitis, as well as septic shock, delayed hypersensitivity, acute respiratory distress syndrome (ARDS), multiple sclerosis, pancreatitis and ischemic cardiac injury.

Immune and inflammatory disorders, which are MIF-related, are gram negative and gram positive sepsis, e.g. *P. aeruginosa* infections or sepsis, DTH, glomerulonephritis, arthritis, adjuvant arthritis, juvenile arthritis, (autoimmune) encephalomyelitis/encephalitis, (autoimmune) myocarditis, allergic encephalitis, gastritis, colitis; (immune)glomerulonephritis; pneumonia, toxic shock syndrome, viral infections, tuberculosis, hepatitis B, dengue fever, parasitic and helminthic MIF-related infections, in particular malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, amoebiasis, schistosomiasis, cysticercosis, trichinellosis and filariasis; kidney diseases, like leukocyte-mediated renal injury, non-proliferative renal disease, proliferative renal disease, renal allograft rejection and congenital nephritic syndrome of the Finnish type, nephritis, nephropathy like uric acid nephropathies and hypertensive nephropathy, ureteric obstruction and diabetic nephropathy.

Neuropathic pain is a further MIF-related disease.

Most preferred diseases to be diagnosed according to the present invention are: glomerulonephritis, sepsis, lymphoma, lupus nephritis, psoriasis, ulcerative colitis and ophthalmological conditions, as well as Burkitt's lymphoma, leukemia, prostate adenocarcinoma, pancreatic adenocarcinoma, and ovarian carcinoma.

One important aspect of the present invention is directed to detection of oxMIF in a sample of a subject; this detection

will allow e.g. the skilled practitioner to determine whether or not MIF is a therapeutically important component of the disease or disorder which afflicts the subject in question. This determination will aid his decision whether or not an (additional) anti-(ox)MIF treatment could be beneficial for the subject in question.

OxMIF is also useful as a marker to determine a health or disease condition of a given subject in general; elevated oxMIF level will allow the finding that the subject is afflicted with a MIF related disease; oxMIF can thus also be used as a (secondary) general marker for a health/disease condition of a subject, similar e.g. to the determination of C-reactive protein (CRP) which is currently and widely used as such a (secondary) marker.

A subset of *in vivo* protective anti-oxMIF mAbs (e.g. RAB9, RAB4 and RAB0), which are directed against the pro-inflammatory cytokine oxMIF (Macrophage Migration Inhibitory Factor) do not bind to unmodified MIF in its reduced state (designated as redMIF). By contrast, these mAbs were shown to be highly selective for a redox dependent MIF isoform (designated as oxMIF). It was shown that oxMIF is not present in blood of healthy subjects and animals. It was also shown that oxMIF is not present on cellular surfaces of healthy subjects and animals. According to the present invention, and by the methods described herein, oxMIF can only be detected after onset of a disease. oxMIF was then (i.e. after onset of disease) shown to appear in the circulation or on the surface of cells. Stated differently: it was shown by the present inventors that oxMIF is clearly increased (i.e. detectable) in the circulation in samples of human or animal patients afflicted with a MIF related disease. It was also shown that oxMIF is strongly increased (and, thus, detectable) on the surface of cells afflicted with MIF related diseases. According to the present

invention, detection of oxMIF in patients provides advantageous information regarding disease progression and therapeutic intervention. Therefore, oxMIF can be used as a diagnostic marker and the herein described methods will enable the monitoring of oxMIF during MIF-related diseases, e.g. affliction of a subject, e.g. a human, with inflammatory conditions or disease states like cancer.

Based on the described findings, the present invention is directed to the use of oxMIF as a marker in the diagnosis of MIF-related diseases. oxMIF is preferably MIF, which is differentially binding, as defined herein above, to antibody RAB9, RAB4 and/or RAB0. As explained above and shown in the experimental part, in particular the examples section, the present inventors showed for the first time that oxMIF is an isoform of MIF, which is encountered patient samples of MIF-related diseases, while it is not encountered, i.e. present as defined above, in normal healthy controls. Thus, oxMIF is most suitable as a marker in the diagnosis of MIF-related diseases. As it was shown by the present invention that oxMIF, in particular the amount thereof, is also correlated with the state of a disease and/or its progression; "diagnosis" in the context of this specification encompasses detection of a disease, evaluation of a disease state and monitoring of a disease progression, which also allows monitoring efficacy of a therapeutic treatment.

In a preferred embodiment, the diagnosis of said MIF-related diseases, which uses oxMIF as a marker, will encompass the further use of compounds binding to oxMIF for the detection of oxMIF.

These compounds, which differentially bind oxMIF can be antibodies or small molecules, which differentially bind to oxMIF.

The diagnostic assay which can be used in the present invention can be any diagnostic assay which is well-known to a person skilled in the art. In particular, the diagnostic assay can be carried out e.g. in an ELISA format, a sandwich (ELISA) format with use of FACS, immunofluorescence, immunohistochemistry , and all further suitable methods, all of which are well-known in the art.

The present invention will be in the following described by way of the examples, whereby the examples shall be considered by no means as limiting the present invention.

REFERENCE EXAMPLES

A) GCO-assay for antibody screening:

A THP1 suspension culture is centrifuged and cells are resuspended in fresh full medium to a cell density of 10^6 cells per ml. This culture is transferred into wells of a 96-well microplate (90 μ l/well) and a potential anti-MIF antibody is added to give a final concentration of 75 μ g/ml. Each antibody is tested in triplicate. After o/n incubation at 37°C dexamethasone is added to give a concentration of 2 nM and after one hour incubation at 37°C LPS is added (3 ng/ml final concentration). After further six hours incubation at 37°C the supernatant is harvested and the IL-6 concentrations are determined in a commercially available ELISA. The results of the triplicates are averaged and the percentage of IL-6 secretion is determined in comparison to the control antibodies. Antibodies that result in an IL-6 secretion of less than 75% are evaluated as positive.

B) Assay for determination of IC₅₀ values

The experimental procedure is carried out as described for the screening assay with the exception that increasing

amounts of antibody are used (typically from 1 - 125 nM). The resultant dose response curve is expressed as % inhibition in comparison to a negative control antibody. This curve is used for calculation of the maximum inhibitory effect of the antibody (%Inh max) and the antibody concentration that shows 50% of the maximum inhibitory effect (IC₅₀).

C) Inhibition of cell proliferation

Serum stimulates secretion of MIF in quiescent NIH/3T3 and MIF in turn stimulates cell proliferation. Antibodies inhibiting this endogenous MIF, therefore, decrease the proliferation of quiescent NIH/3T3 cells. The reduction of proliferation is determined by the incorporation of ³H-thymidine.

1000 NIH/3T3 cells per well are incubated in a 96 well plate over the weekend at 37°C in medium containing 10% serum. Cells are then starved over night at 37°C by incubation in medium containing 0.5% serum. The 0.5% medium is removed and replaced by fresh medium containing 10% serum, 75 µg/ml antibody and 5µ Ci/ml of ³H-thymidine. After 16 hours incubation in a CO₂ incubator at 37°C cells are washed twice with 150 µl of cold PBS per well. Using a multi-channel pipette 150 µl of a 5% (w/v) TCA solution per well are added and incubated for 30 minutes at 4°C. Plates are washed with 150 µl PBS. Per well 75 µl of a 0.5M NaOH solution with 0.5% SDS are added, mixed and stored at room temperature. Samples are measured in a β-counter by mixing 5 ml of Ultima Gold (Packard) and 75 µl sample solution. Each determination is done in triplicate and the values are compared with the values of the control antibody by a t-test. Antibodies that significantly reduce proliferation (P<0.05) are evaluated as positive.

D) Binding studies: Epitope determination of anti-MIF antibodies

Each peptide is diluted in coupling buffer to give a peptide concentration of typically 1 µg/ml added to microplates (NUNC Immobilizer™ Amino Plate F96 Clear) and incubated over night at 4°C (100 µl/well). As controls recombinant full length MIF and PBS are used. The plate is washed 3 times with 200 µl PBST and antibodies (2-4 µg/ml in PBS) are added (100 µl/well) and incubated for 2 hours at room temperature with gentle shaking. The plate is washed 3 times with 200 µl PBST and detection antibody (e.g. Fc specific anti-human IgG/HRP labeled, Sigma) is added (100 µl/well). After incubation for 1 hour at room temperature with gentle shaking, the plate is washed 3 times with 200 µl PBST. Each well is incubated with 100 µl TMB (3,3',5,5'-tetramethylbenzidine) solution (T-0440, Sigma) for 30 minutes in the dark. Staining reaction is stopped by adding 100 µl of 1.8 M H₂SO₄-solution per well. Samples are measured at 450 nm.

E) Affinity determination of Fab fragments of anti-MIF antibodies by Biacore

Typically, 40 RU units of human recombinant MIF are immobilized on a sensor chip with a CM5 (= carboxymethylated dextran) matrix (Biacore). Fab fragments are injected at a concentration range of typically 6 - 100 nM diluted in HBS-EP. After each cycle the chip is regenerated with 50 mM NaOH + 1 M NaCl. Affinities are calculated according to the 1:1 Langmuir model.

EXAMPLES

The present examples relate to the finding that several specific antibodies only bind to oxMIF, but do not bind to

unmodified MIF in a reduced state. This was shown by the detection of oxidized MIF by ELISA after mild oxidation of recombinant MIF by chemicals using a mock preparation, reduced MIF and untreated MIF as controls; this experiment was carried out *in vitro* and clearly showed that oxMIF was bound by specific antibodies, while control MIFs were not.

Anti-oxMIF antibodies RAB4, RAB9 and RAB0 were shown to be incapable of binding to MIF in its reduced state at physiologically relevant concentrations. In contrast, it was shown *in vitro*, that mild oxidation of MIF (e.g. with L-Cystine) can convert the MIF molecule into the antibody-binding isoform. Antibody-based screenings for oxMIF forms in vertebrate systems and cell lines (e.g. immortalized cell lines, plasma from mice, urine from rats, and plasma and urine from human donors) revealed, that the occurrence of such antibody-reactive MIF isoforms is linked to disease related processes (e.g. inflammation and neoplasia). This is why these antibodies can be used as tools for e.g. the diagnostic detection of native occurring disease-related oxMIF forms and for monitoring disease progression.

The present inventors have also shown for the first time that false positive results for oxMIF can be obtained. It is assumed that MIF protein can be converted to oxMIF by redox-active iron and heme in hemolytic blood samples and that MIF can be converted to oxMIF in biosamples, when oxidizing agents are added.

It is thus proposed according to a preferred embodiment for avoiding false positive results to avoid the addition of e.g. oxidizing agents and to de-activate redox-active iron and heme.

For example, a special sample procedure for the analysis of MIF circulating in blood is required. For the analysis of

total and oxMIF, citrated plasma is preferred; to avoid false positive signals the samples in a preferred embodiment have to be prepared by the following steps:

Citrated **plasma** from fresh blood (stored at +4°C not longer than 12 h) has to be centrifuged at 40 g for 5 min. The supernatant has to be transferred into a new tube and centrifuged again at 2000 g for 3 min. The cell free supernatant has to be transferred again into a new tube and centrifuged at 16000 g for 3 min. After the three centrifuge steps, the cell free supernatant can be stored at -80°C or directly used for the analysis of (ox)MIF.

If **sera** should be analyzed regarding (ox)MIF, cells and insoluble fragments preferably have also to be removed by the same three centrifugation steps prior storage by freezing or prior running the MIF ELISA.

Sediments in **urine** samples also preferably have to be removed by a centrifugation step (16000 g for 5 min) prior to use in the MIF ELISAs. Generally, cells and other common particles occurring in biological fluids (e.g. tear fluid, saliva) have to be removed prior by a centrifugation step and then stored for testing of (ox)MIF.

Furthermore, the present inventors could show that MIF which is denatured is recognized by antibodies which specifically bind to oxMIF. Therefore, it is of utmost importance that for analysis of oxMIF, the MIF protein has to be kept in its native conformation during sample preparation (e.g. during the isolation and preparation of body fluids); therefore denaturating conditions/steps such as for example boiling, immobilization (on membranes, plastic (plate) or chips) and chemical treatments (e.g. with reducing agents, oxidizing agents and organic solvents), have to be avoided in order to

keep the MIF protein in its native conformation and to avoid false positive/negative results during the analysis.

For analysis of oxMIF on cellular surfaces, preferably a flow cytometry assay is used. It is particularly important that the samples do not undergo hemolysis during sample preparation. Therefore, all samples for the present flow cytometry analysis have been prepared without any step which would lead to a hemolysis of the cells within the sample.

Example 1: Preparation of oxMIF specific antibodies (e.g. RAB0- or RAB4-Antibody) :

The antibodies are produced in mammalian cells, preferentially in CHO cells, preferentially in CHO cells where the gene encoding for MIF (endogenous CHO-MIF) has been knocked out genetically. In the knock-out cells the contamination of the antibody with endogenous CHO-MIF can be abolished, which is desirable as sensitivity of the assays can be enhanced.

Typically, oxMIF specific antibodies were produced in a batch fermentation process using a disposal bioreactor (wave system) up to 25 L volume. Stable CHO cell lines harboring the genes encoding for the heavy and light chain of the produced antibody, respectively, were seeded into an PowerCHO medium (Invitrogen Inc.) and incubated at 37°C and 5% CO₂.

In one exemplary production process, a CHO knock out cell line was used which comprised plasmids as deposited under DSM 25114 and DSM 25115.

During the cultivation, the respective human antibodies were continuously expressed into the cell culture medium. At the end of cultivation (viability <50%) the cells were separated by common centrifugation and filtration steps. The clarified

cell culture supernatant (ccs) was concentrated by ultrafiltration and used for the purification of antibodies.

The human antibodies were purified from the concentrated ccs by Protein A affinity chromatography (MabSelect Sure, GE Healthcare). After equilibration of the Protein A material with 5 column-volumes (cv) of 20 mM sodium phosphate running buffer, pH 7 the concentrated supernatant of the isotype control was completely applied to the affinity column. Impurities or undesirable proteins were washed out with the running buffer. The antibodies were eluted by a pH shift using 100 mM glycine, pH 3 and dialyzed against 250 mM glycine buffer, pH 5.

Alternatively, the concentrated cell culture supernatant was applied to the Protein A column prior equilibrated with 5 cv of 20 mM Tris/HCl buffer including 150 mM sodium chloride buffer and 0.1% Tween 80, pH 7. Impurities were washed out by two washing steps: 1.) addition of 1 M NaCl in the equilibration buffer and 2.) 100 mM sodium phosphate including 0.1% Tween 80, pH 5. The RAB0 antibodies were eluted by 100 mM glycine buffer, pH 3 including 0.1% Tween 80 and then dialyzed against 250 mM glycine buffer, pH 5.

Example 2: Preparation of polyclonal and affinity purified polyclonal rabbit anti-hu MIF antibodies:

1.) Production of recombinant human MIF (huMIF)

Recombinant huMIF was produced in *E.coli* cells including an expression system with the human MIF sequence. Fresh thaw cells were cultivated in Luria Bertani medium supplemented with Ampicillin (LB/Amp) over night at +37°C. At the next day, the bacterial cell culture was diluted with an equal volume of fresh LB/Amp medium and the expression induced by addition of IPTG (final concentration: 1.0 mM) at 30°C for 4

hours. The bacterial pellet was harvested by centrifugation and stored at $\leq -15^{\circ}\text{C}$.

For further purification of the intracellular human MIF proteins the frozen bacterial pellet was resuspended in 20 mM Tris/HCl buffer, pH 7.8 and cells were disrupted mechanically by glass beads. Cell debris was removed by centrifugation and filtration using a common 0.2 μm filter. The supernatant was directly applied to an anion exchange chromatography column (HiTrap 26/16 DEAE FF, GE Healthcare, Waukesha, USA) and MIF was purified by a passive binding mode. The flow through was rebuffered in 20 mM Bis/Tris pH 6.3 and further purified by a cation exchange chromatography (Source 30S, GE). Highly pure human MIF was eluted by a salt gradient of 50 mM NaCl in 20 mM Bis/Tris buffer, pH 6.3. Finally, the purified human MIF was rebuffered against PBS concentrated by ultrafiltration and characterized of purity and functionality.

2.) Immunization procedure of polyclonal rabbit anti huMIF antibodies in New Zealand White rabbits

For the initial immunization, 25 μg of rec. human MIF diluted in 100 μl PBS was mixed with 100 μl CFA (Complete Freunds Adjuvants). 200 μl (4 x 50 μl) of the mixture was applied s.c. to different body portions of each rabbit. After 2-3 weeks after the initial immunization a first boost with 25 μg of the rec. human MIF (suspended in 100 μl PBS) was mixed with 100 μl IFA (Incomplete Freunds Adjuvants). Again, 200 μl (4 x 50 μl) of the mixture was applied s.c. to different body portions of each rabbit. A second boost was performed 2-3 weeks after the first boost, 25 μg of the rec. human MIF (suspended in 100 μl PBS) was mixed with 100 μl IFA (Incomplete Freunds Adjuvants). Again, 200 μl (4 x 50 μl) of the mixture was applied s.c. to different body portions of each rabbit. The immunization procedure was terminated 2 weeks after the second boost. Typically, plasma from multiple

rabbits was pooled and used for the isolation of the anti MIF antibodies.

3.) Protein A Purification and huMIF-affinity purification procedure of polyclonal rabbit anti humIF antibodies

The isolation of rabbit anti huMIF antibodies from immunized plasma was typically done by two affinity chromatography steps. At first the plasma was purified by a Protein A affinity column (MabSelect Sure, GE Healthcare). To that avail, the rabbit plasma was diluted 1:3 with 20 mM Na₂HPO₄ buffer, pH 7.0 and applied to the affinity column. After a washing step (5 column volumes with 20 mM Na₂HPO₄ buffer, pH 7.0) the elution of total rabbit IgG was done with 100 mM glycine, pH 2.8. The eluate was pooled and neutralized to pH 7.0 using 1 M Tris/HCl. For hu-MIF affinity purification the total rabbit IgG was again diluted 1:3 with 20 mM Na₂HPO₄ buffer, pH 7.0 and applied to the 5 ml NHS-affinity column (GE Healthcare) coupled with 25 mg rhuMIF as recommended by the supplier. After a washing step (5 column volumes with 20 mM Na₂HPO₄ buffer, pH 7.0) the elution of the specific rabbit anti huMIF antibodies was effected with 100 mM glycine, pH 2.8. The eluate was pooled and neutralized to pH 7.0 using 1 M Tris/HCl. Finally, the hu-MIF affinity purified specific rabbit anti human MIF antibodies (in the following "anti-human MIF affinity purified polyclonal antibody") were dialyzed against PBS and stored at -20°C.

Example 3: Detection of oxMIF in samples obtained from patients or from animal disease models:

I. SEPSIS

Example 3.1: oxMIF in plasma of *E.coli*-challenged mice

We sought to look for systemic oxMIF forms in plasma samples of peritonitic mice that had been challenged with 2000 cfu (colony forming units) of the gram negative pathogenic *E.coli* strain O111:B4. Blood samples of healthy mice (treated with PBS) and diseased mice were taken 21 h after challenge and plasma has been analyzed for oxMIF.

Method

Microtiter plates were coated with anti oxMIF antibodies RAB0 or RAB4. MIF was detected with an affinity purified polyclonal rabbit anti-mouse MIF antibody and a commercial HRP conjugated goat anti rabbit IgG. The antibodies were obtained similarly as described in Example 2, but in contrast to the Example 2 the rabbit anti moMIF antibodies were produced by rabbit immunization with recombinant moMIF and purified by affinity chromatography against Protein A and MIF (same procedures as described in Example 2). For quantification of reactive MIF from plasma samples, oxMIF standards are prepared by mixing untreated recombinant moMIF with a buffer (= ELISA dilution buffer) that contains 0.2% of the biocide Proclin300 (Sigma Aldrich). Proclin300 consists of oxidative isothiazolones that induce/conserve the binding oxMIF structure. All plates were developed with TMB (Sigma-Aldrich) and OD was measured in an ELISA reader after stopping the reaction with 3M H₂SO₄.

Results

Figure 1A (Figure 1B).

Analyses of plasma from seven different animal experiments have revealed considerable differences of total MIF and oxMIF levels. However, no oxMIF has ever been detected in plasma of PBS treated control mice (healthy controls), whereas oxMIF was almost always detected in plasma from septic mice. Range

values from seven different experiments have been summarized in Table 1.

Table 1: Ranges of measured total MIF and oxMIF in mice (n=7 expts.)

	Total MIF [ng/ml]	oxMIF [ng/ml]
Control mice	8 - 64	n.d.
<i>E.coli</i> challenged mice	2 - 112	n.d. - 36

Figure 1 shows one representative experiment in which oxMIF was detected only in septic mice with variations in oxMIF levels between mice (Figure 1A). In this experiment total MIF level was elevated in the plasma of one mouse only and a significant portion of the total MIF in this mouse is oxMIF (Figure 1A and 1B, mouse E6), thus confirming that oxMIF is a better diagnostic marker for acute septicaemia than total MIF.

Conclusion

Total MIF is present in both healthy control mice and bacteriemic mice, but oxMIF levels correlate better to the stage of the disease than levels of total MIF.

Example 3.2: oxMIF on the cellular surface of cells from *E.coli*-challenged mice

Immune cells from peritonitic mice (or control mice injected with PBS only) have been analyzed for oxMIF by flow cytometry.

Methods

Blood from PBS- or *E.coli*-challenged mice was stained in Cell Staining Buffer (Biologend) with either Alexa700-labeled anti-CD3ε (for T cells) and PerCP-Cy5.5-labeled anti-Ly6G

(for granulocytes) or APC-labeled anti-CD14 (for monocytes) and PE-Cy7-labeled anti-CD19 (for B cells) in parallel with 300 nM RAB9 or control IgG. After washing, the human antibodies were detected using the goat R-PE-labeled anti-human IgG antibodies. After washing, the red blood cells were lysed with the BD FACSTM Lysing solution (Becton Dickinson, Franklin Lakes, USA). Data acquisition was performed using a FACSTM Canto II (Becton Dickinson) with the DIVA™ software (software version 6; Becton Dickinson) and the data were analyzed using the FlowJo™ software (Treestar, Ashland, OR, USA).

Results

The presence of oxMIF on the surface of the blood cells from peritonitic mice was analysed. Blood was harvested by cardiac puncture after 1, 3 or 21h post-challenge, i.e. PBS for the control group and 2000 CFU *E.coli* for the peritonitic mice. The staining with RAB9 was performed on full blood and red cells were lysed before the analysis. Figure 2 shows the histograms for the control mice (F) and challenged mice (E) at the different time points over a control IgG antibody (black line). In control mice, positive cells were not significantly detected with RAB9 for both, granulocytes-monocytes population and lymphocytes. oxMIF was not detected on the surface of lymphocytes but was present on the surface of both granulocytes (GR1 marker) and monocytes (CD14 marker), as soon as 1 h after challenge and up to 21 h.

Summary and Conclusion

In a peritonitis model in the mouse, we have been able to show the presence of oxMIF on the surface of granulocytes and monocytes during the time of infection and we have shown that oxMIF was not found in PBS-treated animals. These results demonstrate that oxMIF is a marker which appears in the

course of an infection but is not present in healthy individuals.

Example 3.3: Detection of oxMIF in sera of bacteremic patients

Plasma samples from citrated blood were obtained from bacteremic patients treated in intensive care unit (ICU) and have been analyzed for their content in MIF and oxMIF

Material and Methods

Both total MIF and oxMIF were detected using the same ELISA set up: microtiter plates were coated with the human anti-MIF monoclonal antibody RAB0 and detection was done with an affinity purified polyclonal rabbit antibody anti-human MIF. Finally, the read-out of the ELISA was done after incubation of goat anti-rabbit, HRP conjugated (BioRad, Cat.: 171-6516) (any other goat anti-rabbit as known in the art could be used here as well) and TMB substrate (a chromogenic substrate, as defined above; any other suitable substrate could also be used, as known to a person skilled in the art) at 450 nm. The calibration of the ELISA was done with a recombinant human oxMIF which was freshly produced by an oxidation step of redMIF by adding of 0.2% ProClin300. The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 4% human control plasma. The range of the calibration curve is 10 ng/ml to 0.156 ng/ml. The tested human serum samples were diluted 1:25 in 0.5% fish gelatin /PBS, pH 7.2 for oxMIF ELISA, or in the presence of Proclin300 for the total MIF ELISA in order to transform every reduced MIF molecules present in the plasma in oxMIF.

Results

Plasma samples from citrated blood have been obtained from patients treated in an ICU for septicaemia (n=6). Gender, age, infectious germs and treatments are all different.

Figure 3 shows the levels of total MIF and oxMIF detected in the plasma of the patients as well as in one healthy donor or from a pool of 50 plasma samples from healthy donors. Total MIF is present in every sample but oxMIF is detected only in 2 out of 6 bacteremic patients.

Conclusion

oxMIF can be detected in the plasma of some of the bacteremic patients tested (2 out of 6), but not in the plasma of healthy donors. OxMIF can be used as a marker for septicaemia.

II. PSORIASIS

Example 3.4: Detection of oxMIF in sera of psoriasis patients

Sera samples collected from psoriatic patients have been analyzed for their content in oxMIF. The sera were taken from patients with systemic anti-psoriatic therapy at different time points (start, 12 weeks and 24 weeks).

Material and Methods

Measurement of oxMIF in serum by a sandwich ELISA:

Microtiter plates were coated with the monoclonal fully human anti-oxMIF antibody RAB0. The human serum samples were diluted 1:25 in 0.5% fish gelatin/PBS, pH 7.2. The calibration of the ELISA was done with a recombinant human oxMIF which was freshly produced by adding of 0.2% ProClin300. The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 4% human control

plasma (i.e. a pool of serum samples from 50 healthy donors). The range of the calibration curve was 10 ng/ml to 0.156 ng/ml. After washing of the plate, oxMIF captured by the coating antibody was detected by an affinity purified polyclonal rabbit anti-human MIF antibody (rabbit anti-huMIF, does not distinguish between redMIF and oxMIF) and HRP labelled goat anti-rabbit antibodies. TMB was used as chromogenic substrate, chromogenic reaction was stopped with H₂SO₄ and the ELISA plate was measured at 450 nm. All samples, standards and controls, were done in duplicate.

Results

We were able to detect increased levels of oxMIF in serum of patients with psoriasis. During treatment with systemic immunomodulators levels of oxMIF decreased correlating with an improvement of the patient's condition (Figure 4).

Conclusion

oxMIF levels have been detected in serum samples of psoriatic patients. This means that oxMIF is very sensitive in chronic or acute inflammatory skin diseases like psoriasis and can also be used as a marker for the severity of the disease and to monitor disease development during systemic anti-psoriatic therapy.

III. NEPHRITIS

Example 3.5: oxMIF in the urine of rats after establishment of proliferative glomerulonephritis

Material and Methods

Rat model for proliferative Glomerulonephritis:

OxMIF levels were analyzed in urine of Wistar Kyoto (WKY) rats after induction of proliferative glomerulonephritis by application of a single intravenous injection of rabbit anti-rat glomerular basement membrane serum (= nephrotoxic serum, NTS) (Tam FWK, Nephrol Dial Transplant, 1999, 1658-1666). The urine samples were collected using metabolic cages before induction of the disease. Four and six days after induction of disease rats were treated with a human control antibody, or different doses of the human anti-oxMIF antibody RAB9. The second urine sampling was done before sacrificing the animals on day 8 for histological evaluation. OxMIF levels measured in the urine were correlated with other disease parameters like proteinuria or histology data of the kidney (crescent formation and macrophage infiltration).

Measurement of oxMIF in urine by a sandwich ELISA

Microtiter plates were coated with the monoclonal fully human anti-oxMIF antibody RAB0. The urine samples were diluted 1:10 in 2% BSA /TBST pH 7.2. For the standard calibration curve, recombinant moMIF protein was modified by adding 0.2% ProClin300 and the standards were diluted in 2% BSA/TBST including 0.2% ProClin300. Detection was achieved by an affinity purified polyclonal anti-mouse MIF antibody (rabbit anti-moMIF, as described in Example 3.1) and a HRP-conjugated goat anti-rabbit antibodies. TMB was used as chromogenic substrate, chromogenic reaction was stopped with H₂SO₄ and the ELISA plate was measured at 450 nm. All samples, standards and controls, were done in duplicate.

Results

Before disease induction the mean level of oxMIF was not significantly above 0. Four days after disease induction significant levels of oxMIF became detectable. During disease progression the urinary oxMIF levels increased in the

untreated control group on day 8 up to 333 ng/day (mean 130 ng/day). On day 8 the mean level of oxMIF in the anti-MIF antibody treated group was by approx. 70% decreased in comparison to the non treated group (see Figure 5A). The reduced level of oxMIF in the treated group correlated with reduced disease parameters such as proteinuria and macrophage infiltration (Figure 5B).

Conclusion

The level of oxMIF in urine correlates with the disease state in an animal model for proliferative glomerulonephritis. After administration of anti-oxMIF antibody RAB0, oxMIF levels were significantly reduced. Therefore, we conclude that measurement of oxMIF is suitable as a diagnostic marker to monitor disease progression and treatment effectiveness of Nephritis.

Example 3.6: oxMIF in urine and plasma of Lupus Nephritis Patients

Urine and plasma samples were collected from Lupus Nephritis patients at different stages of disease. Each sample was stored frozen at -20°C and shipped on dry ice.

Material and Methods

Preparation of oxMIF specific antibodies:

The same antibody preparations were used as described in Example 1.

Measurement of oxMIF in urine by a sandwich ELISA:

Microtiter plates were coated with the monoclonal fully human anti-oxMIF antibody RAB0. The human urine samples were

diluted 1:10 in 0.5% fish gelatine /PBS, pH 7.2. The calibration of the ELISA was done with a recombinant human oxMIF which was freshly produced by adding of 0.2% ProClin300. The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 10% human control urine (i.e. a pool of urine samples from >10 healthy donors). After washing of the plate, oxMIF captured by the coating antibody was detected by an affinity purified polyclonal rabbit anti-human MIF antibody (rabbit anti-huMIF, does not distinguish between redMIF and oxMIF) and HRP labelled goat anti-rabbit antibodies. TMB was used as chromogenic substrate, chromogenic reaction was stopped with H₂SO₄ and the ELISA plate was measured at 450 nm. All samples, standards and controls, were done in duplicate.

Measurement of oxMIF in plasma by a sandwich ELISA:

Microtiter plates were coated with the monoclonal fully human anti-oxMIF antibody RAB0. The human plasma samples were diluted 1:20 in 0.5% fish gelatin/PBS, pH 7.2. The calibration of the ELISA was done with a recombinant human oxMIF which was freshly produced by adding of 0.2% ProClin300. The standards were diluted in 0.5% fish gelatine/PBS including 0.2% ProClin300 and 5% human control plasma (i.e.. a pool of plasma samples from 150 healthy donors). The range of the calibration curve was 10 ng/ml to 0.156 ng/ml. After washing of the plate, oxMIF captured by the coating antibody was detected by an affinity purified polyclonal rabbit anti-human MIF antibody (rabbit anti-huMIF, does not distinguish between redMIF and oxMIF) and HRP labelled goat anti-rabbit antibodies. TMB was used as chromogenic substrate, chromogenic reaction was stopped with H₂SO₄ and the ELISA plate was measured at 450 nm. All samples, standards and controls, were done in duplicate.

Results

The data depicted in Figure 6A show a clear correlation between the amount of oxMIF detected in the urine and the state (stage) of the disease. The mean level of oxMIF determined in the urine of healthy controls was not significantly above 0. However, the more severe the disease state, the higher the mean oxMIF concentration determined in the urine.

OxMIF levels of an acute patient diagnosed with Lupus Nephritis was measured at first observation day, 9 days and 35 days post diagnosis. Constant reduction in oxMIF levels correlated with improved clinical symptoms (Figure 6B). OxMIF levels in plasma were also measured and the results were comparable to the urinary levels. However, correlation with partly remission, remission or smoldering disease were less pronounced most probably because oxMIF in the circulation reflects overall the activity of the underlying disease (SLE) and not only the situation in the kidney (Figure 6C).

Conclusion

Measurement of oxMIF in urine of lupus nephritis patients is suitable to monitor for disease progression as well as treatment efficiency. OxMIF in the circulation also correlates with disease severity although the result probably reflects the overall situation of the patients regarding SLE and not only the situation in the kidney (LN).

IV. DIABETIC RETINOPATHY

Example 3.7

Aqueous humor samples taken from patients with diabetic retinopathy (DR) and cataract as controls were assayed for the presence of MIF and oxMIF by ELISA.

Material and Methods

Total MIF and oxMIF were detected with the same ELISA set up described in examples 3.3 and 3.4.

Results

As shown on figure 7, total MIF is detected in the samples from DR or cataract patients, but oxMIF is only detected in DR samples.

Conclusion

OxMIF can be used as a marker in diabetic retinopathy.

V. PROSTATE CANCER

Example 3.8: OxMIF in mouse plasma after establishment of a human prostate cancer

Plasma samples were collected at the time of termination of a xenograft mouse prostate cancer model. oxMIF as well as total MIF levels were measured and correlated with tumor growth in isotype control and anti-MIF treated mice.

Material and Methods

Xenograft model for prostate cancer.

PC-3 cells were harvested from exponentially growing cultures and mixed with growth factor-depleted BD matrigel matrix. The suspension was inoculated subcutaneously into the right flank

of MF1 nude mice (2×10^6 cells in 250 μl matrigel per mice, 10 mice per group). One day after tumour induction, antibody treatment with RAB0 was started (5 and 15 mg/kg) and the antibodies were injected i.p. every second day for 2 weeks. Blood was collected by heart puncture and plasma was prepared for measurement the day of circulating MIF levels. Plasma samples from non-xenografted mice were also analyzed for total MIF and oxMIF (= negative control). In addition, tumour weight was measured.

Measurement of total MIF in plasma by a sandwich ELISA:

Microtiter plates were coated with an affinity purified polyclonal rabbit anti-mouse MIF antibody (rabbit anti-moMIF, as described in Example 2). The tested plasma samples were diluted 1:25 in 0.5% fish gelatin/PBS, pH 7.2. The calibration of this ELISA was done by a recombinant full length mouse MIF protein. The standards were diluted in 0.5% fish gelatin/PBS including 4% control plasma. Detection of captured MIF was achieved by an affinity purified and biotinylated polyclonal rabbit anti-mouse MIF antibody (biot. rabbit anti-moMIF). All samples, standard and controls were done in duplicates

Measurement of oxMIF in plasma by a sandwich ELISA:

Microtiter plates were coated with the monoclonal fully human anti-oxMIF antibody RAB0. The plasma samples were diluted 1:25 in 2% BSA /TBST pH 7.2. For the standard calibration curve, recombinant moMIF protein was modified by adding 0.2% ProClin300 and the standards were diluted in 2% BSA/TBST including 0.2% ProClin300 and 4% control plasma. Detection of captured oxMIF was achieved by an affinity purified polyclonal anti-mouse MIF antibody (rabbit anti-moMIF, as described in Example 3.1) and a HRP-conjugated goat anti-rabbit antibodies. TMB was used as chromogenic substrate,

chromogenic reaction was stopped with H₂SO₄ and the ELISA plate was measured at 450 nm. All samples, standards and controls, were done in duplicate.

Results

The median of total MIF in the isotype control treated group did not differ significantly from the anti-MIF antibody treated animals. Levels of total MIF were found to be increased in tumour bearing animals when compared to non-xenografted mice (= negative control in Figure 8A). However, oxMIF levels in healthy animals are not detectable by the methods applied (= negative control in Figure 8B; see also example 3.8). But as depicted in Figure 8B, oxMIF levels were clearly detectable in tumor bearing mice. In addition, oxMIF levels were significantly reduced after treatment with an anti-MIF antibody. The median oxMIF level in the control group was found to be 8.6 ng/mL and was reduced in the two treatment groups. The dose dependent reduction of oxMIF levels also correlated with the reduction in tumor growth, thus with the therapeutic effect achieved (Figure 8C).

Conclusion

In the PC-3 prostate cancer xenograft model, levels of total MIF were found to be increased in tumor bearing mice. However, oxMIF is not detected in non-xenografted control mice and concentration of oxMIF, but not of total MIF, correlates with tumor growth in MF1 nude mice. OxMIF is therefore much more suitable as a diagnostic marker for monitoring disease progression and therapeutic effects than total MIF.

Example 3.9: oxMIF on the cellular surface of a prostate cancer cell line

The human prostate cancer cell line PC-3 (prostate adenocarcinoma, ATCC® CRL-1435™) has been tested by flow cytometry for the expression of oxMIF on its surface.

Methods

Cells were stained in Cell Staining 'Buffer (Biolegend) with 300 nM antibody RAB9 or RAB0 and "Control 1", (irrelevant isotype control antibody) as the negative control, and antibodies were detected with the R-PE anti-human IgG (Sigma).

Human blood from healthy donors was also analyzed to assess the presence of oxMIF on the surface of leukocytes in a "normal" situation. Heparinized blood was first incubated with anti-human Fc Receptors (anti-CD16, anti-CD32 and anti-CD64) to block unspecific binding of the antibody through their Fc domain to the cells. Cells were then incubated with a control IgG1 human monoclonal antibody, with RAB9 or with RAB0. Detection of cell surface bound antibodies was done with an R-PE-labelled rabbit anti-human IgG. In order to differentiate the different leukocyte subpopulations, cells were also labelled with a Pacific Blue-labelled anti-CD45 (pan-leukocyte marker) and an APC-labelled anti-CD19 (B cell marker). Acquisition is done after lysing the red blood cells. Using the size and complexity parameters as well as the CD19 staining, we are able to distinguish between the granulocytes, monocytes, lymphocyte B cells (CD19+ cells) and lymphocyte T cells + Natural Killer cells (CD19neg cells). The acquisition of the data was carried out with a FACS™ CANTO II (Becton Dickinson) and data were analyzed with the FlowJo software (Treestar).

Results

oxMIF can be found on the surface of human prostate cancer cell line PC-3 (Figure 9). Leukocytes from healthy donors (neg. control) do not show any oxMIF on their cell surface (Figure 10).

Conclusion

The presence of oxMIF on the surface of human prostate cancer cells shows that oxMIF can be used as a marker for detection of cancerous cells.

VI. PANCREATIC CANCER

Example 3.10: oxMIF on the cellular surface of pancreatic cancer cell line

The human pancreatic cancer cell line BxPC-3 (Human primary pancreatic adenocarcinoma, Health Protection Agency (HPA) #93120816) has been tested by flow cytometry for the expression of oxMIF on its surface.

Methods

Cells were stained in Cell Staining 'Buffer (Biolegend) with 300 nM antibody RAB9 or RAB0 and "Control 1" (irrelevant isotype control antibody), as the negative control, and antibodies were detected with the R-PE anti-human IgG (Sigma). The acquisition of the data was carried out with a FACSTM CANTO II (Becton Dickinson) and data were analyzed with the FlowJo software (Treestar).

Results

oxMIF can be found on the surface of human pancreatic cancer cell line BxPC-3 (Figure 11). Leukocytes from healthy donors

(neg. control) do not show any oxMIF on their cell surfaces (Figure 10).

Conclusion

The presence of oxMIF on the surface of human pancreatic cancer cells shows that oxMIF can be used as a marker for detection of cancerous cells.

VII. OVARIAN CANCER

Example 3.11: oxMIF on the cellular surface of ovarian cancer cell line

The human ovarian cancer cell line A2780 (Human ovarian carcinoma, HPA # 93112519) has been tested by flow cytometry for the expression of oxMIF on its surface.

Methods

Cells were stained in Cell Staining 'Buffer (Biolegend) with 300 nM antibody RAB9 or RAB0 and "Control 1" (irrelevant isotype control antibody), as the negative control, and antibodies were detected with the R-PE anti-human IgG (Sigma). The acquisition of the data was carried out with a FACSTM CANTO II (Becton Dickinson) and data were analyzed with the FlowJo software (Treestar).

Results

oxMIF can be found on the surface of human ovarian cancer cell line A2780 (Figure 12), but mainly with the monoclonal antibody RAB0. Leukocytes from healthy donors (neg. control) do not show any oxMIF on their cell surfaces (Figure 10).

Conclusion

The presence of oxMIF on the surface of human ovarian cancer cells shows that oxMIF can be used as a marker for detection of cancerous cells.

VIII. LYMPHOMA

Example 3.12: oxMIF on the cellular surface of lymphoma cancer cell line

Different immortalized human lymphoma cell lines (Table 2) have been tested by flow cytometry for the expression of oxMIF on their surfaces.

Table 2: Cell lines that have been positively tested for active MIF by flow cytometry

Name	Reference	Origin
CA46	ATCC® CRL-1648™	Burkitt's Lymphoma
MC/CAR	ATCC® CRL-8083™	B lymphocyte, plasmacytoma myeloma
Raji	ATCC® CCL-86™	Burkitt's Lymphoma
U-937	ATCC® CRL-1593.2™	Histiocytic Lymphoma

Methods

Cells have been stimulated (or not) with 25 µg/ml LPS and 50 µg/ml Dextran sulfate for 24 h up to 72 h. Cells were stained in Cell Staining 'Buffer (Biolegend) with 300 nM antibody RAB9 or RAB0 or RAB4 and "Control 1" (irrelevant isotype control antibody), as the negative control, and antibodies were detected with the R-PE anti-human IgG (Sigma). The acquisition of the data was carried out with a

FACSTM CANTO II (Becton Dickinson) and data were analyzed with the FlowJo software (Treestar).

Results

oxMIF can be found on the surface of human lymphoma cell lines (Figure 13), whereas leukocytes from healthy donors (neg. control) do not show any oxMIF on their cell surfaces (Figure 10).

Conclusion

The presence of oxMIF on the surface of human lymphoma cells shows that oxMIF can be used as a marker for detection of cancerous cells.

IX. SOLID TUMOUR: PROSTATE AND BREAST CANCER

Example 3.13: oxMIF in the plasma from cancer patients

EDTA plasma samples from patients having different kinds of solid tumors (prostate and breast) were obtained from a commercial vendor. The total MIF and oxMIF concentrations were analyzed by sandwich ELISA.

Material and Methods

Both total MIF and oxMIF were detected using the same ELISA set up: microtiter plates were coated with human anti-MIF monoclonal antibody RAM0 and detection of MIF was done with an affinity purified, polyclonal rabbit anti-human MIF antibody. The read-out of the ELISA was done after incubation of the plate with an goat anti-rabbit, HRP conjugated antibody (BioRad, Cat.: 171-6516) (any other goat anti-rabbit could be used here as well) and TMB (chromogenic substrate; any other suitable chromogenic substrate could also be used,

as known to a person skilled in the art) in an ELISA reader at 450 nm. The calibration of the ELISA was done with recombinant human MIF which was incubated with 0.2% ProClin300 (Proclin300 induces the formation of oxMIF epitopes within MIF). The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 5% human control plasma. The range of the calibration curve was 10 ng/ml to 0.156 ng/ml. The tested human plasma samples were diluted 1:20 either in 0.5% fish gelatin /PBS, pH 7.2 for the oxMIF ELISA, or in 0.5% fish gelatin /PBS/0.2% Proclin300 for the total MIF ELISA.

Results

EDTA plasma samples derived from patients diagnosed with prostate cancer (n=14) and breast cancer (n=15) have been purchased from a commercial vendor. EDTA plasma from healthy volunteers (n=49) was used as control. In Figure 14A and 14B levels of total MIF and oxMIF of control samples and prostate cancer samples are shown. As described in the literature, MIF was detected in the plasma from healthy individuals and a significant increase of total MIF in the plasma from prostate cancer patients (*t* test, $p=0.0166$) was observed. However, oxMIF was not detected in the plasma of healthy donors, whereas oxMIF was detected in the plasma samples from the prostate cancer patients (*t* test, $n=0.0016$). A similar pattern was observed in breast cancer samples (Figure 15) with a significant elevation of total MIF ($p=0.0078$) and oxMIF ($p=0.0451$) in the plasma samples derived from breast cancer patients compared to the healthy controls and no oxMIF detection in healthy controls.

Conclusion

Elevated levels of total MIF and oxMIF can be detected in the plasma of patients with prostate and breast cancer. However,

total MIF is also present in the plasma derived from healthy donors, whereas oxMIF cannot be detected in healthy controls. Therefore, oxMIF can be considered as a more specific biomarker to indicate a disease state than total MIF.

X. MULTIPLE SCLEROSIS

Example 3.14: oxMIF in the CSF of multiple sclerosis patients

Cerebrospinal fluid samples derived from patients with different forms of multiple sclerosis were obtained from a commercial vendor. The total MIF and oxMIF concentrations were measured by sandwich ELISA.

Material and Methods

Both total MIF and oxMIF were detected using the same ELISA set up: microtiter plates were coated with human anti-MIF monoclonal antibody RAM0 and detection of MIF was done with an affinity purified polyclonal rabbit anti-human MIF antibody. The read-out of the ELISA was done after incubation of the plate with an goat anti-rabbit, HRP conjugated antibody (BioRad, Cat.: 171-6516) (any other goat anti-rabbit could be used here as well) and TMB (chromogenic substrate, as defined above; any other suitable chromogenic substrate could also be used, as known to a person skilled in the art) in an ELISA reader at 450 nm.

For the CSF samples, the calibration of the ELISA was done with recombinant human MIF which was incubated with 0.2% ProClin300 (Proclin300 induces the formation of oxMIF epitopes within MIF). The standards were diluted in 20 mM Tris/TBST buffer pH 7.2 including 0.2% ProClin300. The range of the calibration curve is 10 ng/ml to 0.156 ng/ml. The tested human CSF samples were diluted 1:10 in 20 mM

Tris/TBST, for the oxMIF ELISA, or in the presence of Proclin300 for the total MIF ELISA.

Results

In the cerebrospinal fluid (CSF) samples as used in this example (Figures 16 A and 16B), oxMIF was not detectable in the CSF from healthy controls, whereas high levels were found in the CSF of MS patients ($p<0.0001$). Also the levels of total MIF were strongly increased in samples from MS patients ($n=49$) as compared to the controls ($n=30$) ($p<0.0001$), but to a certain extent, total MIF was also found in samples from healthy controls.

Conclusion

Elevated levels of total MIF and oxMIF can be detected in the CSF of MS patients. However, total MIF is also present in the CSF derived from healthy donors, whereas oxMIF cannot be detected in healthy controls. Therefore, oxMIF can be considered as an excellent biomarker for multiple sclerosis and as a more specific biomarker than total MIF.

XI. OVARIAN CANCER

Example 3.15: oxMIF in the plasma from ovarian cancer patients

EDTA plasma samples were commercially obtained from patients having different kind of ovarian cancers (clear cell adenocarcinoma, papillary serous adenocarcinoma and serous adenocarcinoma). Their content in total MIF and oxMIF was analyzed by sandwich ELISA.

Material and Methods

Both total MIF and oxMIF were detected using the same ELISA set up: microtiter plates were coated with human anti-MIF monoclonal antibody RAM0 and detection of MIF was done with an affinity purified polyclonal rabbit anti-human MIF antibody. The read-out of the ELISA was done after incubation of the plate with an goat anti-rabbit, HRP conjugated antibody (BioRad, Cat.: 171-6516) (any other goat anti-rabbit as known in the art could be used here as well) and TMB (chromogenic substrate, as defined above; any other suitable chromogenic substrate could also be used, as known to a person skilled in the art) in an ELISA reader at 450 nm. The calibration of the ELISA was done with recombinant human MIF which was incubated with 0.2% ProClin300 (Proclin300 converts MIF to oxMIF). The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 5% human control plasma. The range of the calibration curve is 10 ng/ml to 0.156 ng/ml. The tested human plasma samples were diluted 1:20 in 0.5% fish gelatin/PBS, pH 7.2 for the oxMIF ELISA, or in the presence of Proclin300 for the total MIF ELISA.

Results

Plasma samples from EDTA blood have been purchased from patients diagnosed with ovarian cancer (n=42). EDTA plasma from healthy volunteers (n=19) was used as control. In Figure 17A and 17B levels of total MIF and oxMIF of control samples and ovarian cancer samples are shown. As described in the literature, MIF was detected in the plasma from healthy individuals and a significant increase of total MIF in the plasma from ovarian cancer patients (t test, p=0.0434) was observed. However, no oxMIF was detected in the plasma of healthy donors, whereas oxMIF was detected in the plasma samples from the ovarian cancer patients (t test, p=0.0663). When the statistical analysis is run on specific subtypes of ovarian cancer, a significant increase of MIF in plasma from

serous cystadenocarcinoma over the controls ($p=0.0046$), as well as a significant increase of oxMIF in papillary serous cystadenocarcinoma ($p=0.0438$) and serous cystadenocarcinoma ($p=0.0357$) over the controls was observed.

XII: ULCERATIVE COLITIS AND CROHN'S DISEASE

Example 3.16: oxMIF in the plasma from patients with ulcerative colitis and Crohn's disease

EDTA plasma samples were commercially obtained from patients having different ulcerative colitis (UC) or Crohn's Disease (CD). Their content in total MIF and oxMIF was analyzed by sandwich ELISA.

Material and Methods

Both total MIF and oxMIF were detected using the same ELISA set up: microtiter plates were coated with human anti-MIF monoclonal antibody RAM0 and detection of MIF was done with an affinity purified polyclonal rabbit anti-human MIF antibody. The read-out of the ELISA was done after incubation of the plate with an goat anti-rabbit, HRP conjugated antibody (BioRad, Cat.: 171-6516) (any other goat anti-rabbit as known in the art could be used here as well) and TMB (chromogenic substrate, as defined above; any other suitable chromogenic substrate could also be used, as known to a person skilled in the art) in an ELISA reader at 450 nm. The calibration of the ELISA was done with recombinant human MIF which was incubated with 0.2% ProClin300 (Proclin300 converts MIF to oxMIF). The standards were diluted in 0.5% fish gelatin/PBS including 0.2% ProClin300 and 5% human control plasma. The range of the calibration curve is 10 ng/ml to 0.156 ng/ml. The tested human plasma samples were diluted 1:20 in 0.5% fish gelatin /PBS, pH 7.2 for the oxMIF ELISA,

or in the presence of Proclin300 for the total MIF ELISA.

Results

Plasma samples from EDTA blood have been purchased from patients diagnosed with UC (n=15) or CD (n=21). EDTA plasma from healthy volunteers (n=19) was used as control. In Figure 18A and 18B levels of total MIF and oxMIF of control samples and UC and CD samples are shown. As described in the literature, MIF was detected in the plasma from healthy individuals and a significant increase of total MIF was detected in the plasma from CD patients (*t* test, $p=0.0207$), but not in UC samples ($p=0.1240$). However, no oxMIF was detected in the plasma of healthy donors, whereas oxMIF was detected in the plasma samples from both UC and CD patients (*t* test, $p=0.0417$ and $p=0.0114$, respectively when compared to controls).

Conclusion

For both ulcerative colitis and Crohn's disease patients, it was possible to detect a significant higher amount of oxMIF in the plasma as compared to healthy volunteers. These results show that oxMIF can be used as a biomarker in these diseases

PCT

Print Out (Original in Electronic Form)

(This sheet is not part of and does not count as a sheet of the international application)

0-1	Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared Using	PCT Online Filing Version 3.5.000.225 MT/FOP 20020701/0.20.5.20
0-2	International Application No.	
0-3	Applicant's or agent's file reference	158882aa/npo

1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	13
1-2	line	6
1-3	Identification of deposit	
1-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
1-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
1-3-3	Date of deposit	12 April 2012 (12.04.2012)
1-3-4	Accession Number	DSMZ 25860
1-5	Designated States for Which Indications are Made	All designations
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	13
2-2	line	8
2-3	Identification of deposit	
2-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
2-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
2-3-3	Date of deposit	12 April 2012 (12.04.2012)
2-3-4	Accession Number	DSMZ 25859
2-5	Designated States for Which Indications are Made	All designations

PCT

Print Out (Original in Electronic Form)

(This sheet is not part of and does not count as a sheet of the international application)

3	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
3-1	page	13
3-2	line	7
3-3	Identification of deposit	
3-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
3-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
3-3-3	Date of deposit	12 April 2012 (12.04.2012)
3-3-4	Accession Number	DSMZ 25861
3-5	Designated States for Which Indications are Made	All designations
4	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
4-1	page	13
4-2	line	9
4-3	Identification of deposit	
4-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
4-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
4-3-3	Date of deposit	12 April 2012 (12.04.2012)
4-3-4	Accession Number	DSMZ 25862
4-5	Designated States for Which Indications are Made	All designations
5	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
5-1	page	13
5-2	line	10
5-3	Identification of deposit	
5-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
5-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
5-3-3	Date of deposit	12 April 2012 (12.04.2012)
5-3-4	Accession Number	DSMZ 25863
5-5	Designated States for Which Indications are Made	All designations

PCT

Print Out (Original in Electronic Form)

(This sheet is not part of and does not count as a sheet of the international application)

6	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
6-1	page	13
6-2	line	11
6-3	Identification of deposit	
6-3-1	Name of depositary institution	DSMZ DSMZ–Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
6-3-2	Address of depositary institution	Inhoffenstr. 7B, D-38124 Braunschweig, Germany
6-3-3	Date of deposit	12 April 2012 (12.04.2012)
6-3-4	Accession Number	DSMZ 25864
6-5	Designated States for Which Indications are Made	All designations

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	yes
0-4-1	Authorized officer	Teloni, Monica

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

CLAIMS

1. Use of oxMIF as a marker in the *in vitro* diagnosis of (MIF-related) diseases, wherein oxMIF is MIF which is differentially binding to antibody RAB4, RAB9 and/or RAB0.
2. The use of claim 1 wherein said diagnosis of (MIF-related) diseases further involves the use of compounds differentially binding to the diagnostic marker, which is oxMIF, as defined in claim 1.
3. The use according to claim 2 wherein the compounds are antibodies, specifically binding to oxMIF.
4. The use according to claim 3 wherein the antibodies bind to oxMIF, but do not bind to redMIF.
5. The use according to claim 4 wherein the differential binding is a binding to oxMIF which occurs with a K_D value of less than 100 nM, preferably less than 50 nM, even more preferred less than 10nM and a non-binding to redMIF which is characterized by a K_D of more than 400 nM.
6. The use according to any one or more of claims 1 to 5, wherein the MIF-related diseases are selected from the group comprising: inflammatory diseases and neoplastic diseases.
7. The use according to claim 6 wherein the MIF-related diseases are selected from the group, consisting of colon cancer, prostate cancer, bladder cancer, pancreas cancer, ovarian cancer, melanoma, lymphoma, hepatocellular carcinoma, asthma, ARDS, rheumatoid arthritis, sepsis, IgA nephropathy, glomerulonephritis,

Lupus Nephritis (LN), hepatitis, pancreatitis (+/- acute lung injury), Crohn's disease, ulcerative colitis, gastric ulcer, Alzheimer's disease, multiple sclerosis, Guillain-Barre syndrome, cardiac dysfunction, angioplasty, atherosclerosis, myocarditis, type 1 diabetes, diabetic retinopathy, age-related macula degeneration (AMD), atopic dermatitis, psoriasis, endometriosis, neuropathic pain and/or uveitis.

8. The use according to any one or more of claims 2 to 7 wherein the antibodies are selected from the group consisting of oxMIF binders (like e.g. antibodies RAB4, RAB9 and/or RAB0).
9. The use according to any one of claims 1 to 8, wherein the diagnosis is the diagnosis of the existence of a (MIF-related) disease, the diagnosis of progression of a (MIF-related) disease, the diagnosis of the state of a (MIF-related) disease, and/or the monitoring of effectiveness of a treatment.
10. The use according to any one of claims 1 to 9, wherein the diagnosis is carried out on a body fluid sample of a subject.
11. The use according to any one of claims 1 to 9, wherein the diagnosis is carried out on a cellular sample of a subject.
12. A diagnostic assay for *in vitro* diagnosis of (MIF-related) diseases by detection of oxMIF as defined in claim 1 in a body fluid or a cellular sample of a subject, comprising a step of determining binding of a compound to oxMIF in said sample *in vitro*.


13. The diagnostic assay according to claim 12 wherein the compound binding to oxMIF and the (MIF-related) diseases are as defined in any one or more of claims 2 to 9.
14. The diagnostic assay according to claim 12 or 13, wherein the assay is repeated once or several times during progression, remission and/or treatment of a (MIF-related) disease.
15. Use of a diagnostic kit in the assay of any one or more of claims 12 to 14, wherein the diagnostic kit comprises a compound binding to oxMIF.
16. The use according to claim 15 wherein the kit additionally comprises buffers, controls (e.g. recombinant (ox)MIF), polyclonal anti-MIF antibody, and/or conjugated detection antibody.
17. Anti-MIF antibody, which is selected from the following group:
 - a) a RAB4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25110 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25112,
 - b) a RAB9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25111 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25113,
 - c) a RAB0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25114 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25115,

- d) a RAM4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25861 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25862,
- e) a RAM9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25859 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25860, and/or
- f) a RAM0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25863 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25864.


18. Anti-MIF antibody, which is selected from the following group:

- a) a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO:6,
- b) a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO:5,
- c) a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO:7,
- d) a RAB2 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 4 and a heavy chain amino acid sequence of SEQ ID NO:8,
- e) a RAM4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 14 and a heavy chain amino acid sequence of SEQ ID NO:13,
- f) a RAM9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 12 and a

- heavy chain amino acid sequence of SEQ ID NO: 11,
and/or
- g) a RAM0 antibody, which is characterized by a light
chain amino acid sequence of SEQ ID NO: 10 and a
heavy chain amino acid sequence of SEQ ID NO: 9
- h) or functional equivalents thereof which are
characterized by binding to the same epitope as any
one of the antibodies a) to g) above.
19. Use of any one of the above antibodies, in particular as
defined in claims 17 or 18, in the diagnosis of a (MIF-
related) disease.

Figure 1

Plasma obtained from control mice (C) and *E.coli* challenged mice (E) were subjected to oxMIF (Figure 1A) and total MIF (Figure 1B) ELISAs.

Figure 2




Figure 3

Detection of oxMIF in the plasma of bacteremic patients






Figure 4



Figure 5**A****B**

Figure 6

Means of oxMIF in urine from patients with Systemic lupus nephritis (different stages of the disease)




A**B****C**

Figure 7

DIABETIC RETINOPATHY






Figure 8

8A



8B



8C




Figure 9

oxMIF on the surface of PC-3 prostate cancer cell line




Figure 10

Absence of oxMIF on surface of leukocytes from healthy donors




Figure 11

oxMIF on the surface of BxPC-3 pancreatic cancer cell line




Figure 12

oxMIF on the surface of A2780 ovarian cancer cell line




Figure 13

oxMIF on the surface of human lymphoma cell line





Figure 14

14A Total MIF



14B oxMIF





Figure 15

15A Total MIF



15B oxMIF





Figure 16

16A CSF total MIF



16B CSF oxMIF




Figure 17

Figure 17A




Figure 17B




Figure 17C




Figure 17D




Figure 18

Figure 18A





Figure 18B



INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2012/069598

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

1-19(partially)

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2012/069598

A. CLASSIFICATION OF SUBJECT MATTER
INV. G01N33/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, COMPENDEX, EMBASE, FSTA, INSPEC, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009/086920 A1 (BAXTER INT [US]; BAXTER HEALTHCARE SA [CH]; DYAX CORP [US]; KERSCHBAUM) 16 July 2009 (2009-07-16) cited in the application claims page 13, line 20 - line 25 figures ----- X WO 01/64749 A2 (IDEC PHARMA CORP [US]) 7 September 2001 (2001-09-07) claims -----	1-19 1-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

1 February 2013

27/02/2013

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3046

Authorized officer

Routledge, Brian

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2012/069598
--

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 2009086920	A1	16-07-2009	AU 2008346517 A1		16-07-2009
			CA 2711029 A1		16-07-2009
			CN 101983207 A		02-03-2011
			EP 2231707 A1		29-09-2010
			EP 2548890 A1		23-01-2013
			JP 2011510616 A		07-04-2011
			KR 20100102197 A		20-09-2010
			NZ 586600 A		25-05-2012
			RU 2010132647 A		10-02-2012
			US 2009220521 A1		03-09-2009
			US 2010260768 A1		14-10-2010
			WO 2009086920 A1		16-07-2009
<hr/>					
WO 0164749	A2	07-09-2001	AU 3867701 A		12-09-2001
			US 2003235584 A1		25-12-2003
			US 2006191024 A1		24-08-2006
			WO 0164749 A2		07-09-2001
<hr/>					

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-19(partially)

Antibody RAB4 as defined, use in diagnostic methods/assay to determinine oxMIF.

2. claims: 1-19(partially)

Antibody RAB9 as defined, use in diagnostic methods/assay to determinine oxMIF.

3. claims: 1-19(partially)

Antibody RAB0 as defined, use in diagnostic methods/assay to determinine oxMIF.

4. claims: 18, 19(partially)

Antibody RAB2 as defined, use in diagnostic methods/assay to determinine oxMIF.

5. claims: 17-19(partially)

Antibody RAM4 as defined, use in diagnostic methods/assay to determinine oxMIF.

6. claims: 17-19(partially)

Antibody RAM9 as defined, use in diagnostic methods/assay to determinine oxMIF.

7. claims: 17-19(partially)

Antibody RAM0 as defined, use in diagnostic methods/assay to determinine oxMIF.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/050453 A4

(43) International Publication Date

11 April 2013 (11.04.2013)

(51) International Patent Classification:

G01N 33/68 (2006.01)

(21) International Application Number:

PCT/EP2012/069598

(22) International Filing Date:

4 October 2012 (04.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/545,042	7 October 2011 (07.10.2011)	US
61/624,943	16 April 2012 (16.04.2012)	US
61/668,841	6 July 2012 (06.07.2012)	US

(71) Applicants: **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauer Strasse 130, CH-8152 Glattpark (Opfikon) (CH). **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL, 60015 (US).

(72) Inventors: **THIELE, Michael**; Linke Bahngasse 9/24, A-1030 Wien (AT). **KERSCHBAUMER, Randolph, J**; Hoehenstrasse 19/1, A-3400 Klosterneuburg (AT). **VOELKEL, Dirk**; Stadlbreitener Anger 17, A-1220 Wien (AT). **DOUILLARD, Patrice**; Stuwerstrasse 9/9, A-1020 Wien (AT). **SCHEIFLINGER, Friedrich**; Michelbeuerngasse 4/17, A-1090 Wien (AT).

(74) Agents: **HOFFMANN · EITLE** et al.; Arabellastrasse 4, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))

Date of publication of the amended claims: 6 June 2013



WO 2013/050453 A4

(54) Title: OXMIF AS A DIAGNOSTIC MARKER

(57) Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.

AMENDED CLAIMS

received by the International Bureau on 22 April 2013

1. Anti-MIF antibody, which is selected from the following group:

- a) a RAM9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25859 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25860,
- b) a RAM4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25861 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25862,
- c) a RAM0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25863 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25864,
- d) a RAB4 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25110 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25112,
- e) a RAB9 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25111 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25113, and/or
- f) a RAB0 antibody, characterized by a light chain sequence as deposited by way of plasmid deposition with deposit number DSM 25114 and a heavy chain sequence as deposited by way of plasmid deposition with deposit number DSM 25115.

2. Anti-MIF antibody, which is selected from the following group:
 - a) a RAM9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 12 and a heavy chain amino acid sequence of SEQ ID NO: 11,
 - b) a RAM4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 14 and a heavy chain amino acid sequence of SEQ ID NO: 13,
 - c) a RAM0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 10 and a heavy chain amino acid sequence of SEQ ID NO: 9,
 - d) a RAB4 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 2 and a heavy chain amino acid sequence of SEQ ID NO: 6,
 - e) a RAB9 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 1 and a heavy chain amino acid sequence of SEQ ID NO: 5
 - f) a RAB0 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 3 and a heavy chain amino acid sequence of SEQ ID NO: 7, and/or
 - g) a RAB2 antibody, which is characterized by a light chain amino acid sequence of SEQ ID NO: 4 and a heavy chain amino acid sequence of SEQ ID NO: 8,
 - h) or functional equivalents thereof which are characterized by binding to the same epitope as any one of the antibodies a) to g) above.
3. Use of any one of the above antibodies, in particular as defined in claims 1 or 2, in the diagnosis of a (MIF-related) disease.
4. Use of oxMIF as a marker in the *in vitro* diagnosis of (MIF-related) diseases, wherein oxMIF is MIF which is differentially binding to antibody RAB4, RAB9 and/or RAB0.
5. The use of claim 4 wherein said diagnosis of (MIF-related) diseases further involves the use of compounds differentially binding to the diagnostic marker, which is oxMIF, as defined in

claim 4.

6. The use according to claim 5 wherein the compounds are antibodies, specifically binding to oxMIF.
7. The use according to claim 6 wherein the antibodies bind to oxMIF, but do not bind to redMIF.
8. The use according to claim 7 wherein the differential binding is a binding to oxMIF which occurs with a K_D value of less than 100 nM, preferably less than 50 nM, even more preferred less than 10 nM and a non-binding to redMIF which is characterized by a K_D of more than 400 nM.
9. The use according to any one or more of claims 4 to 8, wherein the MIF-related diseases are selected from the group comprising: inflammatory diseases and neoplastic diseases.
10. The use according to claim 9 wherein the MIF-related diseases are selected from the group, consisting of colon cancer, prostate cancer, bladder cancer, pancreas cancer, ovarian cancer, melanoma, lymphoma, hepatocellular carcinoma, asthma, ARDS, rheumatoid arthritis, sepsis, IgA nephropathy, glomerulonephritis, Lupus Nephritis (LN), hepatitis, pancreatitis (+/- acute lung injury), Crohn's disease, ulcerative colitis, gastric ulcer, Alzheimer's disease, multiple sclerosis, Guillain-Barre syndrome, cardiac dysfunction, angioplasty, atherosclerosis, myocarditis, type 1 diabetes, diabetic retinopathy, age-related macula degeneration (AMD), atopic dermatitis, psoriasis, endometriosis, neuropathic pain and/or uveitis.
11. The use according to any one or more of claims 5 to 10 wherein the antibodies are selected from the group consisting of oxMIF binders (like e.g. antibodies RAB4, RAB9 and/or RAB0).
12. The use according to any one of claims 4 to 11, wherein the diagnosis is the diagnosis of the existence of a (MIF-related) disease, the diagnosis of progression of a (MIF-related) disease, the diagnosis of the state of a (MIF-related) disease,

and/or the monitoring of effectiveness of a treatment.

13. The use according to any one of claims 4 to 12, wherein the diagnosis is carried out on a body fluid sample of a subject.
14. The use according to any one of claims 4 to 12, wherein the diagnosis is carried out on a cellular sample of a subject.
15. A diagnostic assay for *in vitro* diagnosis of (MIF-related) diseases by detection of oxMIF as defined in claim 4 in a body fluid or a cellular sample of a subject, comprising a step of determining binding of a compound to oxMIF in said sample *in vitro*.
16. The diagnostic assay according to claim 15 wherein the compound binding to oxMIF and the (MIF-related) diseases are as defined in any one or more of claims 5 to 12.
17. The diagnostic assay according to claim 15 or 16, wherein the assay is repeated once or several times during progression, remission and/or treatment of a (MIF-related) disease.
18. Use of a diagnostic kit in the assay of any one or more of claims 15 to 17, wherein the diagnostic kit comprises a compound binding to oxMIF.
19. The use according to claim 18 wherein the kit additionally comprises buffers, controls (e.g. recombinant (ox)MIF), polyclonal anti-MIF antibody, and/or conjugated detection antibody.

說 明 書 摘 要

本發明涉及以下認識：巨噬細胞移動抑制因子(MIF)的特定形式 oxMIF 作為(MIF 相關的)疾病中的診斷標記物，例如特別是對疾病進展的監控是有用的。本發明還涉及相應的診斷試劑盒的用途和相應的診斷測定法，並涉及有利的相應抗體。